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Two highly homologous enzymes, cytochrome P450 enzyme 3A4 (CYP3A4) and 
CYP3A5 play predominant roles in drug elimination by metabolizing more than half of 
the marketed drugs. This thesis focuses on pharmacokinetics of anti-infective drugs that 
are CYP3A4/5 substrates, inducers, or inhibitors in order to provide a mechanistic 
understanding of CYP3A4/5-related pharmacokinetic variations.  
In a dose-escalation study in healthy volunteers for daily doses of the anti-tuberculosis 
drug rifapentine, we developed and validated Ultra Performance Liquid 
Chromatrography-Mass Spectrometry (UPLC-MS)-based quantitation assays for 
measurement of plasma concentrations of rifapentine and the comparator drug, rifampin, 
and their desacetyl metabolites. We identified a less-than-proportional increase in 
rifapentine plasma peak concentration (Cmax) and area under the plasma concentration-
time curve (AUC) as the rifapentine dose increased from 5 mg/kg to 20 mg/kg. Co-
administration of rifapentine decreased AUC of a CYP3A4/5 substrate drug, midazolam, 
in a dose-independent manner and the reduction was bigger than that caused by the co-
administration of rifampin. 
Ritonavir is a CYP3A4/5 inhibitor used in fixed combination with several anti-HIV drugs 
to prolong their half-lives by inhibiting CYP3A4/5-mediated metabolism of those drugs. 
We conducted a drug-drug interaction study to evaluate the effect of ritonavir-boosted 
anti-HIV drug lopinavir (LPV/r) on the anti-malarial drug quinine, which has a narrow 
therapeutic window. We developed a High Performance Liquid Chromatrography 
(HPLC) interfaced with fluorescence detector assay for simultaneous measurement of 
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plasma concentrations of quinine and its major pharmacologically active metabolite, 3-
hydroxyquinine. We found that LPV/r significantly decreased the exposure of quinine 
and 3-hydroxyquinine, in both total and protein-bound free forms. The finding highlights 
the complex nature of the influence exerted by LPV/r on CYP3A4/5 and other drug-
metabolizing enzymes involved in quinine disposition including UDP-
glucuronosyltransferase, and P-glycoprotein. 
Through studying metabolism of the anti-HIV drug maraviroc, we found CYP3A5 was 
the principal enzyme responsible for the formation of an abundant metabolite, namely, 
M1. The M1 formation capacity of CYP3A5 was 23 times higher than that of CYP3A4 in 
vitro. Further, human liver microsomes isolated from donors with two loss-of-function 
CYP3A5*3 alleles exhibited a 79% decrease in M1 formation as compared to those with 
two wild-type CYP3A5*1 alleles. These results indicate that maraviroc can be used as a 
chemical phenotyping probe to examine CYP3A5 activity in vitro. The excellent safety 
profile of maraviroc allowed us to further examine the utility of maraviroc to assess 
CYP3A5 activity in clinical settings with potential for use as a phenotyping probe. 
Following an oral dose of 300 mg maraviroc, people with two CYP3A5*1 alleles had 
41% lower maraviroc AUC and 66% higher apparent clearance compared with those who 
do not have CYP3A5*1 allele. Subjects who do not have CYP3A5*1 allele had > 2 times 
the AUC ratio of maraviroc to its M1 metabolite compared with those who carry at least 
one CYP3A5*1 allele. Strong correlations between plasma concentration ratios and AUC 
ratios of maraviroc to M1 were observed from 4 to 10 h following the dose with R2 > 
0.87. These results suggest that maraviroc has the potential to be used in clinical studies, 
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possibly with single-point blood collections after the dose, to determine CYP3A5 
activity.  
In conclusion, we characterized the changes in pharmacokinetics of CYP3A4/5 substrate 
drugs caused by anti-infective agents that are CYP3A4/5 inducers or inhibitors; and 
discovered a novel use of maraviroc to assess activity of the highly variable enzyme 
CYP3A5 in both in vitro and in clinical settings. The results from this thesis inform 
several anti-infective dosing regimens and provide a phenotyping tool for identification 
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Chapter 1 – Introduction: Importance of Cytochrome P450 3A in Drug Metabolism and 
Pharmacokinetics 
Cytochromes P450 (CYP) are a superfamily of heme-containing enzymes. They were 
discovered from rat liver microsomes in the 1950s as a pigment with a characteristic 
absorbance at 450 nm1. The CYP enzymes are found in almost all living organisms. 
Eukaryotic CYP enzymes are usually anchored in membranes of cellular endoplasmic 
reticulum2. In humans, they are predominantly expressed in liver but are also found in 
other tissues including intestine, lungs, kidneys, brain, etc3,4. The CYP enzymes catalyze 
biotransformation of large number of endogenous and exogenous compounds to more 
polar compounds to facilitate their excretion into bile or urine5. The typical reaction that a 






similarity at amino acid level9, thereby having a great overlap in enzyme activity and 
substrate spectrum. The relative contributions of CYP3A4 and CYP3A5 to drug 
metabolism are usually indistinguishable; the two enzymes are thus commonly described 
as CYP3A4/5 or CYP3A enzymes. Variations in CYP3A-mediated drug metabolism 
could lead to variability in pharmacokinetics of the substrate drugs. The major sources of 
the variations come from drug-drug interactions and genetic polymorphisms. 
Drug-drug interactions account for 30% of all adverse drug reactions which are the fourth 
leading cause of death and cause > 100,000 annual deaths in US10,11. On one hand, when 
two or more co-administered drugs are metabolized by a single CYP enzyme, they may 
exhibit competitive binding to the enzyme, resulting in inhibition on metabolism of one 
or both of the drugs, leading to elevated plasma levels; similar results could occur when 
one of the co-administered drugs is a CYP substrate while the other one is an inhibitor of 
that enzyme. Under both situations, if the drug that has an elevated plasma concentration 
has a narrow therapeutic index, drug-related toxicities could occur. On the other hand, 
however, the substrate drug plasma concentrations may decrease to sub-therapeutic level 
if it was co-administered with an enzyme inducer, leading to loss of desired drug 
response. Sometimes, changes of plasma concentrations towards either direction lead to 
undesired situations. For CYP3A enzymes, over a half of the marketed drugs are their 
substrates. Moreover, a large amount of drugs in the market have been identified as 
CYP3A inducers or inhibitors. In addition, citrus fruit, alcohol, herbal and dietary 
supplements also have modulatory effects on CYP3A activity12,13. Therefore, CYP3A-
mediated drug-drug interactions are highly likely to happen, which warrants clinical 
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studies to characterize the inductive or inhibitory effect of CYP3A to inform dosing 
regimens so that undesirable consequences can be prevented.  
CYP3A5 exhibits highly variable expression due to its genetic polymorphism. The wild 
type CYP3A5*1 allele is associated with the highest expression level whereas changes in 
the mRNA splicing site due to single nucleotide polymorphisms (CYP3A5*3, 
CYP3A5*6) or in the reading frame due to a T insertion (CYP3A5*7) result in lower 
expression or no activity14-17. CYP3A5*2 had a nucleotide transition from C to A, 
causing an amino acid change from threonine to asparagine in the CYP3A5 protein so 
that the enzyme is not fully functional18. The most common nonfunctional allele 
CYP3A5*3 is abundantly present in the European American population 80-90% of whom 
are CYP3A5 non-expressors because they are homozygous carriers of CYP3A5*3 alleles. 
In contrast, CYP3A5*1 has high frequency in the African American population and > 
60% of them express CYP3A5 by carrying at least one wild-type allele CYP3A5*116,18-20. 
In individuals who are expressors, CYP3A5 protein accounts for > 50% of total liver 
CYP3A and even several-fold higher than that of CYP3A421,22. Increased risk of 
toxicities for some drugs has been reported in people with low CYP3A5 expression23-26. 
Conversely, unexpected high expression of CYP3A5 could result in low blood drug 
concentrations leading to compromised drug efficacy and even life-threatening treatment 
failure. Therefore, measuring CYP3A5 activity using a selective substrate has the 
potential to inform the rational design of drugs that can be preferentially metabolized by 
CYP3A4 versus the highly variable CYP3A5. Such a substrate will also help to identify 
drugs that are CYP3A5 inhibitors or inducers to prevent toxicity or treatment failure in 
multi-drug using patients. 
4 
 
The following four chapters in this thesis aim to study pharmacokinetic variations 
introduced by CYP3A-mediated drug-drug interactions and CYP3A5 genetic 
polymorphisms, and to identify a selective substrate drug that can be used both in vitro 
and in vivo to determine activity of the highly variable enzyme CYP3A5. Chapter 2 and 
Chapter 3 investigate the pharmacokinetic changes of CYP3A substrate drugs when they 
are co-administered with a CYP3A inducer and a CYP3A inhibitor, respectively; Chapter 
4 investigates the anti-HIV drug maraviroc as a chemical probe that can differentiate the 
metabolic activity of CYP3A5 from that of CYP3A4; and finally, in Chapter 5, we 
extended the use of maraviroc as a CYP3A5 phenotyping probe from in vitro to in vivo 
by evaluating the effects of genetic variations of CYP3A5 on pharmacokinetics of 
maraviroc and its major oxidative metabolite. Our findings from this thesis will help to 
understand and characterize pharmacokinetic variations introduced by CYP3A enzymes 











Chapter 2 –Effects of daily dosing regimen of rifapentine on the pharmacokinetics of 
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Rifapentine is an antituberculosis drug that may shorten treatment duration when 
substituted for rifampin. The maximal tolerated daily dose of rifapentine and its potential 
for cytochrome 3A4 induction and autoinduction at clinically relevant doses are 
unknown. We performed a phase I dose-escalation study in healthy volunteers with daily 
doses ranging from 5 to 20 mg/kg. Using 10 mg/kg rifampin as a comparator drug and 
midazolam as a CYP3A probe, we evaluated the effect of rifapentine on CYP3A activity. 
UPLC-MS/MS based quantitation methods were developed and validated to measure 
plasma concentrations of rifapentine, rifampin, and their desacetyl metabolites. 
Rifapentine was tolerated at doses as high as 20 mg/kg/day. Steady-state rifapentine 
concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma 
concentration–time curve (AUC0–24) and maximum concentration (Cmax) were similar in 
the 15- and 20-mg/kg cohorts. Although rifapentine pharmacokinetics appeared to be 
time-dependent, accumulation occurred with daily dosing. The mean AUC0–12 of oral 
midazolam was reduced by 93% with the coadministration of rifapentine and by 74% 
with the coadministration of rifampin (p < 0.01). Changes in the oral clearance of 
midazolam did not vary by rifapentine dose. In conclusion, rifapentine pharmacokinetics 
was less than dose-proportional, and its CYP3A induction was robust. 
Abbreviations 
UPLC-MS/MS, ultra-performance liquid chromatography–tandem mass spectrometry; 
MRM, multiple reaction monitoring; ESI, electrospray ionization; QC, quality control; 
LLOQ, low limit of quantitation; AUC0–24, area under the plasma concentration–time 
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curve from time 0 to 24hr; Cmax, maximum or peak concentration; DMSO, dimethyl 
sulfoxide; FDA, Food and Drug Administration 
Introduction 
Tuberculosis is a major global health problem and remains a leading cause of death from 
an infectious disease27. In 2009, there were an estimated 9.4 million new cases and 1.7 
million deaths from tuberculosis28. The current first-line regimen for tuberculosis was 
developed decades ago, and standard “short course” therapy with isoniazid, rifampin, 
pyrazinamide, and ethambutol must be given for 6 months. The long duration is 
challenging for patients and costly to tuberculosis programs.  
Rifapentine belongs to family of rifamycin antibiotics. It is a cyclopentyl analogue of 
rifampin, the key sterilizing agent in the standard tuberculosis treatment regimen that 
kills bacteria by inhibiting DNA dependent RNA polymerase. Rifapentine has higher 
anti-microbial potency with a lower mean inhibitory concentration against 
Mycobacterium tuberculosis and a longer half-life than rifampin. It was approved by the 
Food and Drug Administration (FDA) for treatment of tuberculosis at a dose of 600 mg 
twice weekly (in intensive phase) and once weekly (in continuation phase). Rifapentine is 
being investigated as a potent tuberculosis drug that may allow reduction in the duration 
of tuberculosis treatment required for cure.  
In a well-established mouse model of tuberculosis, bactericidal and sterilizing activity of 
rifapentine was enhanced as dose and frequency of administration increased. Therapeutic 
regimens that include rifapentine can cure tuberculosis in mice in 3 months or less when 
at least 10 mg/kg are given daily in combination with pyrazinamide and either 
moxifloxacin or isoniazid29,30. Recent studies in immunodeficient mice have shown that, 
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at the same mg/kg dose, rifapentine produces negative lung cultures more quickly and 
protects better against the emergence of isoniazid resistance as compared with rifampin31. 
Therefore, rifapentine holds promise as a drug agent that can shorten treatment duration 
in an exposure-dependent manner. 
In humans, the optimal rifapentine dose and regimen are unknown. Clinical trials using 
current rifapentine dosing regimen have shown unacceptably high relapse rates in some 
patient populations, and the use of higher and/or more frequent doses is probably 
necessary to achieve acceptable cure rates32-34. Because rifapentine was initially 
developed and licensed as an intermittently dosed tuberculosis drug, the maximally 
tolerated daily dose has not been determined, and the dose-linearity of rifapentine 
concentrations with daily dosing has not been established. Furthermore, the impact of 
increasing rifapentine doses on induction of cytochrome P450 metabolizing enzyme 
activity has not been assessed. Like rifampin, rifapentine induces cytochrome P450 
enzyme activity and may also induce its own metabolism or clearance35-38.  
We conducted a phase I, open-label, dose-escalation trial of rifapentine in healthy 
volunteers to evaluate the maximal tolerated daily dose of rifapentine (up to a maximum 
of 20 mg/kg); the pharmacokinetics of higher daily doses of rifapentine; the relationship 
between dose and autoinduction of rifapentine metabolism or clearance; and the 
association between rifapentine dose and induction of CYP3A metabolizing enzymes. 






Materials and Methods 
Reagents  
HPLC-grade solvents were obtained from the following suppliers: acetonitrile from J. T. 
Baker; dimethyl sulfoxide (DMSO) from Sigma-Aldrich; water from Thermo Fisher 
Scientific Inc. Ammonium formate was purchased from Sigma-Aldrich; internal 
standards rifampicin-d3 and rifaximin-d6 from Toronto Research Chemicals Inc. 
(Toronto, ON, Canada; Figure 2-1). Rifapentine, desacetyl rifapentine, rifampin and 
desacetyl rifampin were provided by sanofi-aventis (Figure 2-2). 
Methods 
Study population  
The subjects were healthy adults 18–65 years of age, recruited in Baltimore, MD. The 
eligibility criteria included negative tests for HIV and hepatitis C virus antibodies, and 
normal liver function tests. Those with serum creatinine > 1.5 mg/dl, albumin < 3.5 g/dl, 
hemoglobin < 12.0 g/dl (men) or < 11.0 g/dl (women), neutrophil count < 1,250/mm3, 
platelet count < 125,000/mm3, or positive pregnancy test were excluded. All eligible 
subjects provided written informed consent. The study was approved by the institutional 
review boards of the Johns Hopkins University School of Medicine and the Centers for 




Figure 2-1. Chemical structures of internal standards. (A) Rifampicin-d3 for assay of 
rifapentine and desacetyl rifapentine. (B) Rifaximin-d6 for assay of rifampin and 
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Clinical study design 
This was a phase I open-label, multiple-dose, pharmacokinetic dose-escalation study. 
Sequential cohorts of six subjects received oral rifapentine at 5, 10, 15, or 20 mg/kg 
daily. Another six subjects were enrolled in a 10 mg/kg rifampin comparator arm. All the 
subjects received two single oral doses of midazolam 15 mg on study days 1 
(administered alone) and 15 (coadministered with rifapentine or rifampin) (Figure 2-3). 
The assigned dose of rifapentine or rifampin was administered after a low-fat (865 kcal, 
20% (20 g) fat, 5.1 g fiber) breakfast on study days 2–15. Plasma samples for 
pharmacokinetic analysis were collected before and at 0.5, 1, 2, 4, 5, 8, 12 and 24 h after 
each midazolam dose and the first doses of rifapentine or rifampin. Blood samples at 34, 
48, and 72 h were also collected after the last doses of rifapentine or rifampin. Samples 
for calculating trough concentrations were collected after 1, 5, 8, and 13 doses of 
rifapentine. rifapentine dosing started at 5 mg/kg and was escalated by 5 mg/kg for each 
successive cohort either up to 20 mg/kg or until the maximal tolerated dose, the dose at 
which dose-limiting toxicities (grade ≥ 3 drug-related adverse events occurred in at least 
two subjects) was reached. Adverse events were graded in accordance with the National 
Cancer Institute Common Toxicity Criteria, version 2.0. In this study, the prespecified 
maximum rifapentine daily dose was 20 mg/kg because the results of preclinical 


























Blood sample processing 
Ten ml of blood was collected by venipuncture into a BD Vacutainer tube containing 158 
USP units sodium heparin. After collection, the tube was inverted gently 10 times to mix 
the anticoagulant, and placed on ice. Within 30 min of collection, samples were 
centrifuged (1500 × g, 10 min, 4°C), supernatant plasma was equally aliquotted into two 
sterile 1.8 ml cryovials, and stored at −80°C in the dark.   
Preparation of stock solutions, calibration standards and quality control samples 
All master stock solutions were prepared in DMSO: rifapentine and desacetyl rifapentine 
at 10 mg/ml; rifampin and desacetyl rifampin at 2 mg/ml; internal standards rifampicin-
d3 and rifaximin-d6 at 1 mg/ml. Working solutions were serial dilutions of master stocks 
into DMSO. Calibration standards and quality controls were prepared by spiking freshly-
made working solutions into heparinized plasma. Calibration range was linear from 
100−50,000 ng/ml for rifapentine; 70−35,000 ng/ml for desacetyl rifapentine; and 
100−25,000 ng/ml for rifampin and desacetyl rifampin. Stock solutions, calibration 
standards and quality control samples were stored at −80°C in the dark until use. 
Measurement of plasma concentrations for drugs and metabolites 
Plasma midazolam and 1-OH-midazolam concentration levels were determined using a 
validated high-performance liquid chromatography–mass spectrometry procedure that 
has been previously described39. Absolute recovery of midazolam and 1-OH-midazolam 
from plasma was 95% and 92%, respectively. The plasma standard curve ranged from 
0.1 ng/mL to 500 ng/mL for midazolam and 1-OH-midazolam. For midazolam, intra-day 
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and inter-day precisions were within 11.4%. For 1-OH-midazolam, intra-day and inter-
day precisions were within 11.7%. Accuracy was within 10% for both midazolam and 1-
OH-midazolam.  
To determine concentrations of rifapentine, rifampin and their metabolites, patient 
samples, standards, and quality controls were thawed (1 h, dark), vortexed, and processed 
at room temperature.  For rifapentine and its desacetyl metabolite, 20 µL of plasma was 
placed into a glass tube and 350 µL of acetonitrile containing 17 ng/mL internal standard 
rifampicin-d3 was added. To remove denatured proteins, samples were vortexed (5 s) 
then centrifuged (3000 × g, 10 min) and supernatant was transferred into HPLC vials 
(Waters, Milford, MA). Samples above the upper limit of quantitation were diluted, 1:3 
sample:heparinized blank plasma, and re-evaluated. For rifampin and its desacetyl 
metabolite, 50 µL of plasma was combined with 20 µl of 250 ng/mL internal standard 
rifaximin-6, in wells of a 96-well plate. The plate was vortexed, 30 µL aliquots were 
transferred into a 96-well filtration plate (Agilent Captiva 0.45 µm polypropylene, Lake 
Forest, CA), diluted with 350 µL acetonitrile containing 0.5 mg/mL ascorbic acid, 
vortexed and vacuum filtered. Filtrates were collected into a round collection plate (1 
mL, Waters) which was sealed with a pierceable adhesive foil sheet. The autosampler 
was maintained at 7 ºC. 
Chromatographic and mass spectrometric conditions 
Plasma concentrations of rifapentine, rifampin, and their desacetyl metabolites were 
determined by a liquid chromatography-mass spectrometry assay with Waters ACQUITY 
UPLC interfaced to an AB SCIEX QTRAP 5500 mass spectrometer. The autosampler 
was covered with foil to protect samples from light. Aliquots of 1 µL were injected onto a 
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2.5 µm Waters XTerra MS 2.1 × 50 mm C18 column. Analytic resolution was achieved at 
a flow rate of 0.4 ml/min with chromatography at room temperature. Mobile phases were 
5 mM ammonium formate in water (A) and 3% DMSO in acetonitrile (B), programmed 
at 10% B from 0 to 1.6 min, 10−99% B from 1.6 to 3 min, 99% B from 3 to 9 min, and 
10% B from 9.1 to 10 min. The liquid chromatography was continued several minutes 
after elution of analytes and internal standards for minimization of sample carryover. 
Detection of the analytes and internal standards was achieved via multiple reaction 
monitoring. The mass-to-charge ratios of characteristic ion pairs (precursor > product) 
and individually optimized voltages are presented in Table 2-1. Retention times for 


















m/z† of Ions 
 Operating 
Parameters 
Precursor Product  DP‡ CE§ CXPll  
Rifapentine 2.90 ± 0.005 877.4 845.4  106 27 24 
Desacetyl rifapentine 2.73 ± 0.005 835.3 803.4  76 21 22 
Rifampin 2.75 ± 0.004 823.3 791.4  21 23 30 
Desacetyl rifampin 2.61 ± 0.005 781.3 749.4  31 17 42 
Rifampicin-d3  2.75 ± 0.004 826.4 794.3  46 25 22 
Rifaximin-d6 3.04 ± 0.005 792.2 760.3  11 33 18 
*Mean ± standard deviation 
†m/z, mass-to-charge ratio 
‡DP, Declustering Potential, V 
§CE, Collision Energy, eV 










Mass spectrometry data processing and quantitation 
The data were acquired and analyzed by Analyst® software (Version 1.5.1, AB Sciex, 
Foster City, CA)) in Windows XP Professional Version 2002. Using the peak areas, the 
peak area ratios of analyte to internal standard were determined for each calibrator to 
generate the calibration curves.  The 1/x2 weighting was selected for the best fit of the 
data. The peak area ratio, intercept and slope (y = mx+b, y = peak area ratio, m = slope, x 
= concentration, and b = intercept) were used to determine the QCs and unknown 
specimen concentrations.  
Determination of accuracy and precision 
Accuracy, the measure of exactness to the target concentration, is reflected by deviation 
(%) and calculated by dividing the difference between the experimental concentration 
(EC) and the theoretical concentration (TC) by the theoretical concentration and finally 
multiplying by 100 (Equation 5-1).  
% Dev = [(EC – TC)/TC] x 100     Equation 5-1 
Precision, the measure of the degree of repeatability, is defined as the coefficient of 
variation (%CV), which is the standard deviation (SD) divided by the mean (M) 
multiplied by 100 (Equation 5-2). 
%CV = (SD/M) x 100       Equation 5-2 
The precision and accuracy was determined using the 5 different runs that assessed 
linearity. Within each run, LLOQ, low QC, medium QC, and high QC were analyzed six 
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times. The intra-run precision and accuracy results were calculated by using the quality 
control samples within each run. 
Determination of Extraction Efficiency 
Extraction efficiency was determined by the recovery of the analytes or internal standard 
using two sets of samples, pre-extracted and post-extracted samples. Each set of samples 
were prepared using six different lots of plasma at concentrations of low, medium and 
high QCs. For the first set, plasma samples were spiked with analytes or internal standard 
prior to the extraction; whereas for the post-extracted samples, blank plasma samples 
were extracted and then spiked with the analytes or internal standard. The recovery was 
calculated as: 
Recovery (%) = (peak area of pre-extracted samples/peak area of post-extracted samples) 
× 100 
Freeze-thaw Stability Test 
Three replicates of low and high quality control samples were stored at –20°C for 24 
hours then thawed on a lab bench at room temperature. When the samples were 
completely thawed, the same samples were put back into the freezer under the previous 
conditions.  For rifapentine and desacetyl rifapentine, the freeze-thaw cycles were 
repeated 5 times for the low QC and 6 times for the high QC before the samples were 
analyzed. For rifampin and desacetyl rifampin, the freeze-thaw cycles were repeated for 3 
times for both low and high QCs. The results of the samples that went through the freeze 
thaw cycle (treated) were compared to the results of the samples that were made fresh on 
the day of the analysis.   
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Sample matrix stability 
Three replicates of the low QC and three replicates of the high QC samples were thawed 
and kept at room temperature on a laboratory bench for 2 days and then they were 
analyzed. The results obtained from this analysis were compared to samples of equivalent 
concentrations that were prepared fresh on the day of the analysis.   
Injection matrix stability 
The stability of rifampin, rifapentine and their desacetyl metabolites in the injection 
matrix was assessed by analyzing the samples immediately and then allowing them to 
remain at room temperature for three days. The samples were then reanalyzed and their 
concentrations calculated using the calibration curve from the first analysis. These results 
were then compared to the samples that were made on the original day of the analysis.   
Partial volume validation 
Partial volume validation was conducted in two different ways. To mimic samples that 
may be beyond the range of the calibration curve, human heparin plasma samples were 
spiked with the analytes at 3 times the highest calibrator concentration and then diluted 
with blank plasma at ratios of 1:4, 1:8 and 1:16; to mimic samples that may have 
insufficient sample volume for analysis, the medium and high QCs were diluted with 
blank plasma at ratios of 1:2 and 1:4. Six replicates of each sample were diluted and 
analyzed.  
Statistical considerations and pharmacokinetic analysis  
21 
 
Pharmacokinetic parameters of rifapentine, rifampin, and midazolam (and their 
metabolites), including AUC, Cmax, T1/2, apparent clearance (CL/F), and volume of 
distribution (V/F), were calculated using standard noncompartmental methods and 
WinNonlin software, version 6.1 (Pharsight, Cary, NC). The values of time to Cmax were 
computed from the respective concentration-time curves. The mean accumulation index, 
Rac, namely, the ratio of the multiple-dose AUC0–24 to the single-dose AUC0–24, was 
calculated for each dosing cohort. For testing the time invariance of the drug kinetics, the 
mean ratio of the multiple-dose AUC0–24 to the single-dose AUC0–inf (AUC0–24hss/AUC0–
infsd) was estimated. Statistical analyses were performed using SAS (version 9.2; SAS 
Institute, Cary, NC). The Student’s t-test was used for comparison of pharmacokinetic 
parameters and an analysis of variance test for analyzing the differences in 















Noise background, chromatography and linearity of quantitation assays 
The noise background for the interested analytes and internal standard was first evaluated 
in the blank plasma. The signals were minimal at the expected retention time of the 
analytes and the internal standard. Representative chromatograms of rifapentine, 
desacetyl rifapentine, and the internal standard are shown in Figure 2-4. The signal to 
noise ratios of LLOQ for all four analytes are ≥ 3 (Figure 2-5). Calibration range was 
linear from 100−50,000 ng/mL for rifapentine; 70−35,000 ng/mL for desacetyl 
rifapentine; and 100−25,000 ng/mL for rifampin and desacetyl rifampin. Depiction of the 
linearity of the assay is presented in Figure 2-6. The r2 values from five independently 












Figure 2-4. Chromatograms of the analytes and internal standard in blank plasma. 
The data are the extracted ion currents of each of the transitions employed for the LC-
MS/MS analysis. Top to bottom are rifapentine (RPT) at 877.378>845.401, desacetyl 

















Figure 2-5. Chromatograms of rifapentine and des-rifapentine and internal 
standard at LLOQ.  Concentrations of rifapentine and desacetyl rifapentine are 100 
ng/mL and 70 ng/mL, respectively. Top to bottom are rifapentine (RPT), desacetyl 

















Figure 2-6. Representative calibration curves of rifapentine and desacetyl 
rifapentine. Top panel is rifapentine (RPT) and bottom panel is desacetyl rifapentine 
des-RPT). The y-axis represents the peak area ratio of corresponding analytes to the 






Precision, accuracy, recovery, and stability of the quantitation assays 
For rifapentine, as shown in Table 2-2, the inter-run precision and accuracy of the LLOQ 
were 8.6% and 2.3%, respectively; the intra-run precision of LLOQ ranges from 3.0% to 
10%; the inter-run precision and accuracy values for the low, medium, and high QCs 
were ≤ 7.9% for precision and within ± 9.9% for accuracy; and the intra-run precision 
values of the QCs were ≤ 11%. The recovery of rifapentine from human plasma was ≥ 
75% from the test of low, medium and high QCs. After repeated freeze-thaw cycles, the 
low and high QCs only had 5% and 1.1% changes, respectively, when compared to the 
samples that did not go through these procedures. This indicated that the freeze-thaw did 
not significantly affect the stability of rifapentine. For the sample matrix test, rifapentine 
was stable at room temperature in dark in plasma for 2 days with the % change of the low 
QC and high QC at -5.6% and -2.7%, respectively. Furthermore, after the samples were 
processed and left in the injection matrix at room temperature for 3 days, the changes of 
rifapentine low and high QCs were 0.34 % and -4.7%, respectively.  For partial volume 
validation test, the precision for rifapentine was ≤ 5.5 %, while the accuracies were all 
within ± 8.0% for all dilutions (Table 2-3). 
For desacetyl rifapentine, as shown in Table 2-4, the inter-run precision and accuracy of 
the LLOQ were 13% and 3.9%, respectively; the intra-run precision of LLOQ ranges 
from 6.3% to 17%; the inter-run precision and accuracy values for the low, medium, and 
high QCs were ≤ 8.2% for precision and within ± 7.4% for accuracy; and the intra-run 
precision values of the QCs were ≤ 13%. The recovery of desacetyl rifapentine from 
human plasma was found to be ≥ 83% by testing low, medium and high QCs. After 3 
repeated freeze-thaw cycles, the low and high QCs only had changes of 0.7% and 0.4%, 
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respectively, comparing to the samples that did not go through these procedures. For the 
sample matrix test, rifapentine was stable at room temperature in dark in plasma for 2 
days with the % change of the low QC and high QC at -8.0% and -7.3%, respectively. 
Furthermore, sample injection matrix test suggested that the changes of desacetyl 
rifapentine concentrations were -11.6 % and -7.1%, respectively, for low and high QCs, 
after the samples were processed and left in the solution at room temperature for 3 days. 
For partial volume validation test, desacetyl rifapentine had precisions of ≤ 6.5 % and 
accuracies of within ± 5.0 % for all sample dilutions (Table 2-5). 
For rifampin, as shown in Table 2-6, the inter-run precision and accuracy of the LLOQ 
were 10% and -5.8%, respectively; the intra-run precision of LLOQ ranges from 6.9% to 
13%; the inter-run precision and accuracy values for the low, medium, and high QCs 
were ≤ 7.2% for precision and within ± 4.0% for accuracy; and the intra-run precision 
values of the QCs were ≤ 9.1%. The recovery of rifampin from human plasma was ≥ 
105% for low, medium and high QCs. After repeated freeze-thaw cycles, the 
concentration changes of low and high QCs were 3.0% and 7% changes, respectively, 
comparing to the samples that did not go through these procedures. For the sample matrix 
test, rifampin was stable at room temperature in dark in plasma for 1 day with the % 
change of the low QC and high QC at -7.5% and -4.3%, respectively. Furthermore, after 
the samples were processed and left in the injection matrix at room temperature for 4 
days, the changes of rifampin concentrations at low, medium, and high QCs were -10.9%, 
7.7%, and -9.24%, respectively.  For partial volume validation test, the precision of 




For desacetyl rifampin, as shown in Table 2-8, the inter-run precision and accuracy of the 
LLOQ were 11% and -2.4%, respectively; the intra-run precision of LLOQ ranges from 
2.4% to 16%; the inter-run precision and accuracy values for the low, medium, and high 
QCs were ≤ 8.7% for precision and within ± 9.2% for accuracy; and the intra-run 
precision values of the QCs were ≤ 12%. The recovery of desacetyl rifampin from human 
plasma was ≥98% for low, medium and high QCs. After 3 repeated freeze-thaw cycles, 
the concentration changes of low and high QCs were 6.0% and 4.1%, respectively, 
comparing to the samples that did not go through these procedures. For the sample matrix 
test, desacetyl rifampin was stable at room temperature in dark in plasma for 1 day with 
concentration changes of the low QC and high QC at -3.8% and -7.7%, respectively. In 
addition, the changes in desacetyl rifampin concentrations for low, medium and high QCs 
were -1.0%, -11.3, and -10.5%, respectively, after the samples were processed and left in 
the solution at room temperature for 4 days. For partial volume validation test, desacetyl 
rifampin had precisions of ≤ 9.5 % and accuracies of within ± 5.2 % for all sample 
dilutions (Table 2-9).  
The data indicated that we have successfully developed and validated this method for the 
analysis of rifapentine, rifampin and their desacetyl metabolites in plasma samples.  







Table 2-2.  Stability, recovery, accuracy, and precision of rifapentine. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 100 300 25,000 40,000 
Freeze-Thaw* (% change) N 5.0 N 1.1 
Stability† (% change) N -5.6 N -2.7 
Recovery (%) N 75 78 86 
Accuracy‡ (%) 2.3 9.9 3.0 -2.5 
Intra-run Precision‡ (ranges of CV) 3.0-10 2.9-11 0.1-7.8 4.5-7.9 
Inter-run Precision‡ (CV) 8.6 7.9 7.0 6.3 
Injection Matrix Stability# N 0.34 N -0.73 
 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*Low, 5 cycles; High, 6 cycles; N = not determined 
†Room temperature in dark for 2 days 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 








Table 2-3. Partial volume validation results of rifapentine.  
 Medium QC High QC 3 × ULOQ 




24000 25120 42200 42400 145600 163200 168000 
26200 25160 38000 42800 156400 164800 144320 
26200 27600 39200 40400 152800 158400 161600 
25000 26440 38000 40800 154400 163200 159360 
25600 28040 39200 42400 144800 163200 168000 
24400 26360 42400 39920 156800 159200 164800 
Theoretical Value 
(ng/mL) 
25000 25000 40000 40000 150000 150000 150000 
Mean (ng/mL) 25233 26453 39833 41453 151800 162000 161013 
SD 924 1208 1986 1224 5317 2567 8874 
% CV 3.7 4.6 5.0 3.0 3.5 1.6 5.5 
% Dev 0.9 5.8 -0.4 3.6 1.2 8.0 7.3 









Table 2-4.  Stability, recovery, accuracy, and precision of desacetyl rifapentine. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 70 210 17,500 28,000 
Freeze-Thaw* (% change) N 0.7 N 0.4 
Stability† (% change) N -8.0 N -7.3 
Recovery (%) N 98 83 90 
Accuracy‡ (%) 3.9 7.4 -0.2 -5.1 
Intra-run Precision‡ (ranges of CV) 6.3-17 2.3-13 3.2-7.7 2.3-6.0 
Inter-run Precision‡ (CV) 13 8.2 6.6 6.4 
Injection Matrix Stability# N -11.6 N -7.1 
 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*Low, 5 cycles; High, 6 cycles; N = not determined 
†Room temperature in dark for 2 days 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 








Table 2-5. Partial volume validation results of desacetyl rifapentine.  
 Medium QC High QC 3 × ULOQ 




17480 17240 26400 30360 100000 115200 112480 
17220 17960 25800 26760 96000 108000 102080 
17000 17800 26400 29200 103600 104800 102400 
16860 17560 25600 25160 104000 104000 110080 
15800 18120 28200 28320 100400 110400 110080 
17000 17880 27400 27960 100000 119200 115200 
Theoretical Value 
(ng/mL) 
17500 17500 28000 28000 105000 105000 105000 
Mean (ng/mL) 16893 17760 26633 27960 100667 110267 108720 
SD 578 315 991 1828 2914 5974 5364 
% CV 3.4 1.8 3.7 6.5 2.9 5.4 4.9 
% Dev -3.5 1.5 -4.9 -0.1 -4.1 5.0 3.5 









Table 2-6.  Stability, recovery, accuracy, and precision of rifampin. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 100 300 12,500 20,000 
Freeze-Thaw* (% change) N 3.0 N 7.0 
Stability† (% change) N -7.5 N -4.3 
Recovery (%) N 126 105 107 
Accuracy‡ (%) -5.8 -3.9 4.0 0.2 
Intra-run Precision‡ (ranges of CV) 6.9-13 5.0-8.0 0.2-7.2 3.8-9.1 
Inter-run Precision‡ (CV) 10 7.2 6.4 6.9 
Injection Matrix Stability# N -10.9 7.7 9.2 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*Low and High, 3 cycles; N = not determined 
†Room temperature in dark for 1 day 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 










Table 2-7. Partial volume validation results of rifampin.  
 Medium QC High QC 3 × ULOQ 




11880 13160 18640 18920 70800 74640 75520 
12800 13400 18580 18120 72800 70240 81920 
11940 12720 20400 18520 76400 75040 69120 
12160 12440 19220 19880 75200 82400 73920 
11560 12640 21400 21240 80400 78240 80640 
11880 11600 19760 21920 74000 78640 83040 
Theoretical Value 
(ng/mL) 
12500 12500 20000 20000 75000 75000 75000 
Mean (ng/mL) 12037 12660 19667 19767 74933 76533 77360 
SD 420 628 1094 1536 3305 4176 5421 
% CV 3.5 5.0 5.6 7.8 4.4 5.5 7.0 
% Dev -3.7 1.3 -1.7 -1.2 -0.1 2.0 3.2 











Table 2-8.  Stability, recovery, accuracy, and precision of desacetyl rifampin. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 100 300 12,500 20,000 
Freeze-Thaw* (% change) N 6.0 N 4.1 
Stability† (% change) N -3.8 N -7.7 
Recovery (%) N 98 99 104 
Accuracy‡ (%) -2.4 -4.8 9.2 6.0 
Intra-run Precision‡ (ranges of CV) 2.4-16 4.6-11 3.5-6.6 3.3-12 
Inter-run Precision‡ (CV) 11 7.4 6.2 8.7 
Injection Matrix Stability# N -1.0 -11.3 -10.5 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*Low and High, 3 cycles; N = not determined 
†Room temperature in dark for 1 day 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 











Table 2-9. Partial volume validation results of desacetyl rifampin.  
 Medium QC High QC 3 × ULOQ 




12480 12200 19580 18600 69600 72160 73760 
12660 13840 20600 17520 70800 71200 80800 
12520 13120 16680 21040 68400 69520 63520 
12140 12920 21600 19960 73200 83200 80000 
11960 13080 22000 22560 71600 75280 72320 
12420 10840 19680 21680 72800 73680 69760 
Theoretical Value 
(ng/mL) 
12500 12500 20000 20000 75000 75000 75000 
Mean (ng/mL) 12363 12667 20023 20227 71067 74173 73360 
SD 262 1037 1909 1911 1853 4848 6488 
% CV 2.1 8.2 9.5 9.5 2.6 6.5 8.8 
% Dev -1.1 1.3 0.1 1.1 -5.2 -1.1 -2.2 












Study population and safety of daily dosing rifapentine 
Of 37 enrolled participants, 33 received at least one dose of rifapentine or rifampin. 
Among these 33, 7 (21%) were females, median age (interquartile range) was 45 (38, 52) 
years, median weight was 78 (69, 85) kg, and median body mass index was 26 (24, 29) 
kg/m2; the majority were African American (22 [69%]) or Caucasian (10 [31%]). 
Twenty-nine completed both inpatient pharmacokinetic sampling visits, and 28 were 
included in the pharmacokinetic analysis (one was excluded from pharmacokinetic 
analyses for apparent non-adherence). Median rifapentine doses by cohort were 450, 750, 
1200, and 1650 mg. Clinical symptoms related to study rifamycins were rarely reported, 
and there were no grade 2 or higher clinical adverse events.  Grade 2 or higher laboratory 
toxicities occurred in 9 (27%) of the participants. Dose-limiting toxicities were observed 
in three subjects, one each in the rifampin, rifapentine 10 mg/kg, and rifapentine 15 
mg/kg cohorts. The symptoms and laboratory abnormalities resolved without specific 
intervention. As there were not two or more dose-limiting toxicities in any dosing cohort, 
dose escalation proceeded to the predefined maximum dose of 20 mg/kg. There was no 
specific toxicity that increased in frequency or severity with increases in rifapentine dose. 
The dose effect on pharmacokinetics of rifapentine and desacetyl rifapentine 
The mean plasma concentrations of rifapentine after the first and after 14 consecutive 
daily doses of rifapentine are shown in Figure 2-7, by dosing cohort. The median 
rifapentine single-dose Cmax and AUC0-24 increased nearly dose-proportionally from 5 
mg/kg to 15 mg/kg but were similar in the 15 and 20 mg/kg cohorts (Table 2-10). 
Exposures to rifapentine at steady-state after 14 consecutive doses increased less than 
dose-proportionally with two-fold, three-fold, and four-fold increases in dose resulting in 
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only 1.38-, 2.29-, and 2.17-fold increases in Cmax and 1.51-, 2.57-, and 2.22-fold 
increases in AUC0-24, respectively (Table 2-11). At the maximum dose tested (20 mg/kg), 
the median steady state Cmax, AUC0-24, and T1/2 were 34.1 µg/mL, 483 µg·h/mL, and 16.0 
hours, respectively. Median single-dose Cmax and AUC0-24 of desacetyl rifapentine 
increased nearly dose-proportionally with increases in rifapentine dose from 5 to 15 
mg/kg but were similar in the 15 and 20 mg/kg cohorts (Figure 2-8 and Table 2-12). 
After 14 daily doses of rifapentine, however, desacetyl rifapentine AUC0-24 increased 
1.31-fold, 3.21-fold, and 2.15-fold with 2-, 3-, and 4-fold increases in rifapentine dose, 
respectively, and ratios were similar for Cmax. There were no significant associations 
between rifapentine or desacetyl rifapentine pharmacokinetic parameters and observed 
toxicities.  
Autoinduction by rifapentine and rifampin  
Upon repeated once-daily dosing, the mean (% coefficient of variation [CV]) 
accumulation index (Rac) was 1.52 (29), 1.40 (29), 1.68 (42), and 1.27 (20); The AUC0-24 
at steady state divided by the AUC0-inf after a single dose (AUC0-24hss/AUC0-infsd) was 
0.84 (37), 0.86 (33), 0.82 (40), and 0.56(39), for the 5, 10, 15, and 20 mg/kg rifapentine 
cohorts, respectively. The AUC0-24hss/AUC0-infsd in 15 mg/kg and 20 mg/kg cohorts were 
statistically significantly different from 1 (p = 0.049 and 0.003, respectively). Combining 
the cohorts, the mean estimated AUC0-24hss/AUC0-infsd was 0.76 (38), and was 
statistically significantly different from 1 (p = 0.0012), indicating that rifapentine 
pharmacokinetics is time-dependent. With multiple dosing, T1/2 decreased (22.9 vs. 16.7 
hs, p = 0.01), and clearance increased (23.5 vs. 32.0 mL/h/kg, p = 0.02), when compared 
to single dose values.   
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Plasma concentrations for both rifampin and desacetyl rifampin were lower after multiple 
doses than after a single dose (Figure 2-9). Five out of six patients did not have 
measurable rifampin and desacetyl rifampin concentrations at 24 h. Median steady-state 
rifampin AUC0-12, Cmax, and T1/2 were 45.2 µg·h/mL, 7.5 µg/ml, and 2.4 h, similar to 
values seen in other studies (Table 2-13)41. The Rac for rifampin was 0.58 (37), and the 
AUC0-12hss/AUC0-infsd was 0.58 (37), which was statistically different from 1 (p = 0.001).  
Effects of daily dosing rifapentine or rifampin on the pharmacokinetics of 
CYP3A4/5 substrate drug midazolam 
The plasma concentration-time curves of midazolam and its major mono-oxygenated 
metabolite, 1-OH-midazolam, when midazolam was taken alone and together with either 
rifampin or rifapentine are presented in Figure 2-10. Concentrations of both midazolam 
and the metabolite were reduced when midazolam was given together with rifamycins in 
all cohorts. The pharmacokinetic parameters are summarized in Table 2-14. Mean Cmax 
of midazolam was diminished by 74% by co-administration with rifampin and by 82%, 
84%, 84%, and 87% by co-administration with rifapentine 5, 10, 15, or 20 mg/kg (Figure 
2-11). Mean AUC0-12 of midazolam was diminished by 75% when co-administered with 
rifampin and by 92%, 92%, 93%, and 91%, respectively, when given together with 
steady-state rifapentine dosed at 5, 10, 15, or 20 mg/kg. Combining all rifapentine dose 
cohorts, midazolam oral clearance increased by 1750% in the rifapentine arms and 925% 
in the rifampin arm (p = 0.05). The half-life of midazolam is decreased by 56% in the 





Figure 2-7. Plasma concentration-time profiles of rifapentine after the first dose (A) 
and 14 daily doses (B) of rifapentine. The values represent arithmetic means with SE 




















Table 2-10. Median (interquartile range, IQR) pharmacokinetic parameters of 
rifapentine following single doses of rifapentine.  
 
 
Single Dose of Rifapentine (mg/kg) 
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Table 2-11. Median (interquartile range, IQR) pharmacokinetic parameters of 
rifapentine following 14 consecutive doses of rifapentine.  
 
Daily Doses of Rifapentine (mg/kg) 
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Figure 2-8. Plasma concentration-time profiles of desacetyl rifapentine after the first 
dose (A) and 14 daily doses (B) of rifapentine. The values shown represent arithmetic 
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means with SE bars; desRPT stands for desacetyl rifapentine. Y axis is in different scales 
















Table 2-12. Median (interquartile range, IQR) pharmacokinetic parameters of 
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Figure 2-9. Plasma concentration-time profiles of rifampin (A) and desacetyl 
rifampin (B) after the first dose and 14 daily doses of rifampin. The values shown 




















Table 2-13. Median (IQR) pharmacokinetic parameters of rifampin and desacetyl 
rifampin after a single dose and after 14 consecutive daily doses of 10 mg/kg 
rifampin.   
Parameter Single dose Multiple doses 
Rifampin   
Cmax (µg/mL) 10.5 (9.3-12.3) 7.5 (5.5-10.1) 
Tmax (h) 2.0 (1.0-4.0) 4.0 (1.9-4. 0) 
AUC0-12 (µg·h/mL) 57.5 (55.9-66.2) 45.2 (26.4-53.9) 
AUCinf (µg·h/mL) 66.4 (58.5-72.4) 47.4 (27.1-59.7) 
T1/2 (h) 3.0 (2.6-4. 0) 2.4 (1.9-3.1) 
Clearance (mL/h/kg) 9.2 (8. 3-10.3) 13.0 (10.1-22.1) 
V/F (mL/kg) 36.8 (33.7-46.0) 49.2 (44.7-57.6) 
Desacetyl rifampin   
Cmax (µg /mL) 1.3 (1.0-1.8) 0.9 (0.4-1.3) 
Tmax (h) 4.0 (4.0-5.0) 4.0 (4.0-5.0) 








Figure 2-10. Plasma concentration-time profiles of midazolam (A) and 1-OH-
midazolam. The values shown represent arithmetic means with SE bars; MDZ, MDZOH, 






















Table 2-14. Median (IQR) midazolam and 1-OH-midazolam pharmacokinetic parameters alone and together with rifapentine by 
dosing cohort.   
Doses 5 mg/kg (N=5) 10 mg/kg (N=5) 15 mg/kg (N=6) 20 mg/kg (N=6) 






























































































































































Table 2-15. Median (IQR) midazolam and 1-OH-midazolam pharmacokinetic 
























 Alone With Rifampin 
Midazolam 
Cmax (ng/mL) 40.8 (34.8-48.7) 9.8(7.2-13.6) 
AUC0-12  (ng·h/mL) 151 (116-197) 26.9 (10.0-55.8) 
T1/2 (h) 4.1 (3.5-5.7) 1.7(1.1-4.4) 
CL/F  (mL/h/kg) 93.3 (70.1-125) 560 (243-1503) 
V/F (mL/kg) 501 (381-596) 1289 (795-2155) 
1-OH-midazolam 
Cmax (ng/mL) 20.3 (13.8-23.4) 7.1 (2.7-12.3) 
Tmax (h) 1.1 (1.0-1.9) 2.0(1.0-2.0) 
AUC0-12  (ng·h/mL) 64.7 (54.9-88.2) 30.1 (9.7-38.0) 
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Figure 2-11. Decreased Cmax and AUC0–12 of midazolam and 1-OH-midazolam by 
rifampin or rifapentine. Cmax (A) or AUC0-12 (B) values of midazolam co-administered 
with steady-state rifampin or rifapentine relative to midazolam administered alone are 
shown on vertical axis. The horizontal axis was labeled with the amount of dosing 
(mg/kg) followed by the drug name rifampin (RIF) or rifapentine (RPT). AUC0-12, area 
under the concentration–time curve from time 0 to 12 h; Cmax, maximum concentration; 























In this dose-escalation study in healthy volunteers, the maximal tolerated daily dose of 
rifapentine was at least 20 mg/kg. The average dose administered in this cohort (1,650 
mg daily) is the highest daily dose of rifapentine tested to date in humans and 
substantially higher than the Food and Drug Administration–approved dose of 600 mg 
twice weekly. The approved dose has been associated with increased risk of tuberculosis 
relapse among high-risk patients with tuberculosis and, in some populations, with relapse 
with acquired rifamycin monoresistance32,34,42,43. The optimal rifapentine dose and 
schedule for treating tuberculosis in humans have not been established, but the mouse 
model suggests that rifapentine bactericidal and sterilizing activity increases virtually 
without plateau up to doses of 160 mg/kg and that daily dosing improves 
outcomes29,31,38,44. The pharmacokinetic/pharmacodynamic parameters and targets 
necessary to achieve cure without relapse in humans are yet to be determined, but in vitro 
and in vivo pharmacodynamic studies suggest that the killing of the bacilli by rifamycins 
is concentration dependent45. Taken together, the preclinical and clinical data suggest that 
the likelihood of rifapentine contributing to a treatment-shortening regimen would be 
highest if rifapentine is given at the highest dose consistent with acceptable safety. In this 
study, we found no specific toxicities that increased with increasing rifapentine dose. The 
safety profile of rifapentine appeared to be similar to that of rifampin 10 mg/kg, which is 
a widely used rifamycin dose; however, the sample size was too small to allow for firm 
conclusions to be made about safety. The safety and pharmacokinetic data from this study 
support the evaluation of daily doses of rifapentine as high as 20 mg/kg in patients with 
tuberculosis. Safety can be assessed more fully among patients taking multidrug therapy 
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of standard duration, and pharmacokinetic/pharmacodynamic correlates can be explored 
to optimize dosing for future pivotal studies. 
From a pharmacokinetic perspective, we found that increases in rifapentine dosage 
resulted in less-than-dose-proportional increases in single-dose and multiple-dose Cmax. 
This suggests a decrease in bioavailability with increasing doses, especially at the highest 
doses. The mechanisms for this are not readily obvious but may include solubility and 
dissolution limits of multiple coadministered rifapentine tablets; saturability of transport 
across the gut wall; dose-dependent upregulation of hepatic or gut presystemic 
biotransformation or clearance (although this effect would have to occur even with a 
single dose); and sampling error. Rifampin, a close structural analog of rifapentine, is 
subject to a first-pass effect (presystemic biotransformation or clearance) that is saturated 
at a daily dose of 300–450 mg, resulting in higher-than-dose-proportional increases in 
concentrations at daily doses > 450 mg46. Our data suggest that this phenomenon does not 
extend to rifapentine, at least at the doses tested in this study. This may be of clinical 
concern if the treatment-shortening potential of rifapentine can be achieved only with 
exposures higher than those achieved by a dose of 15 mg/kg. A given mg/kg dose may 
result in lower rifapentine concentrations in patients with tuberculosis than in healthy 
volunteers, and therefore the dose at which maximum exposures will be achieved may be 
higher in patients with tuberculosis47.  
With repeated dosing, concentrations of rifampin decreased, accompanied by shorter 
half-life and higher oral clearance when compared with single doses, demonstrating that 
rifampin’s pharmacokinetics is time-dependent, which is consistent with previous 
observations48. As described previously, decreases in exposure levels of rifampin and its 
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metabolite at steady state probably result from increased gut and/or hepatic clearance 
with or without secondary biotransformation of the metabolite46,49. In our study, there 
was evidence that the pharmacokinetics of rifapentine was time-dependent, with shorter 
half-life and higher clearance at steady state as compared with after a single dose, and 
with AUC0–24hss/AUC0–infsd < 1. The mechanism for time-dependent pharmacokinetics (or 
autoinduction) has not been fully elucidated with respect to either rifampin or rifapentine, 
but rifamycins are known to be strong inducers of pregnane X receptor, the activation of 
which leads to a cascade of downstream events, including upregulation of P450 enzymes, 
phase II enzymes, and transporters50,51. Up-regulation of metabolizing enzymes or 
transporters (including gut or hepatic P-glycoprotein efflux transporters or hepatic 
OATP1B1 influx transporters) could be responsible for the increases in clearance seen 
with multiple dosing51,52. However, increased production of the enzymes that metabolize 
rifamycins is unlikely to be solely responsible for this because concentrations of the 
desacetyl rifapentine metabolite also decline with multiple dosing. Increased biliary 
clearance of desacetyl rifampin occurs with multiple dosing53, and this phenomenon may 
partially explain decreases in desacetyl rifapentine in response to increases in the dose of 
the parent drug from 15 to 20 mg/kg. Further work is needed to elucidate the mechanisms 
through which rifamycins “autoinduce” their metabolism and/or clearance. Of note, 
despite evidence of time-dependent oral clearance, accumulation of rifapentine occurred 
with daily dosing in contrast to rifampin, a drug with a much shorter half-life. 
Rifamycins are promiscuous, potent inducers of metabolizing enzymes and transporters. 
The use of a rifamycin-containing tuberculosis regimen complicates medical therapy of 
other diseases by reducing the concentrations of coadministered drugs, such as 
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antiretrovirals used in treating HIV. CYP3A enzymes are expressed in both enterocytes 
and hepatocytes and are involved in the metabolism of approximately half of all currently 
licensed drugs. Midazolam is a benzodiazepine that is metabolized by hydroxylation to 1-
OH-midazolam, a reaction mediated almost exclusively by CYP3A54,55. Midazolam is 
commonly used as a probe drug to determine whether a candidate drug affects CYP3A 
enzyme activity and therefore would be expected to affect drug clearance of a CYP3A 
substrate56. When administered orally, midazolam can be used to evaluate the effect of a 
drug on overall CYP3A activity (presystemic plus systemic, comprising induction or 
inhibition of both gut and liver CYP3A)55. In this study, rifampin at standard doses 
increased midazolam clearance eight fold, as has been seen in other studies57,58; 1-OH-
midazolam concentrations were also reduced when midazolam was coadministered with 
rifampin or rifapentine. Increases in midazolam clearance were higher with 
coadministered rifapentine than with coadministered rifampin. This was an unexpected 
finding because in vitro studies have shown rifampin to be more potent than rifapentine 
in inducing CYP3A59. However, this is not surprising, given that steady-state 
concentrations of rifapentine (Cmax: 22 μg/mL and area under the plasma concentration–
time curve (AUC): 330 μg·h/mL) are much higher than for rifampin (Cmax: 7.5 μg/mL 
and AUC: 45 μg·h/mL) for the same mg/kg dose. On a micromolar scale, the average 
concentrations of rifampin and rifapentine at 10 mg/kg were 2.3 and 15.7 μmol/L, 
respectively. There was no evidence of a dose–response relationship between rifapentine 
dose and CYP3A induction at the doses studied. These data suggest that 
recommendations for dose adjustments resulting from drug–drug interaction studies 
involving rifampin and companion drugs may not lend themselves to ready extrapolation 
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to rifapentine. Careful testing of interactions involving rifapentine at clinically relevant 
doses and drugs metabolized by key cytochrome P450 enzymes will help guide dosing 
considerations in the future. 
Our study had some limitations. First, the small sample size did not allow for full 
characterization of the safety and toxicity of rifapentine at different doses. However, 
there was no evidence of dose-dependent increases in specific toxicities that are common 
to the rifamycin class. To assess safety fully, these doses could be tested for a longer 
duration in patients with tuberculosis who are on multidrug therapy. Second, the single-
dose sampling scheme may have prevented accurate estimation of the AUC0–inf, thereby 
affecting evaluation of the time dependence of rifapentine pharmacokinetics. However, 
there was no evidence of a gamma elimination phase after 24 h in the multiple-dose data, 
and it is therefore likely that single-dose AUC0–inf estimates using 24 h data were 
reasonably well approximated. Third, the complex relationships between rifapentine dose 
and the pharmacokinetics of the parent drug and its metabolite, including time and dose 
dependencies and covariate effects are best assessed using nonlinear mixed effects 
modeling. These secondary analyses will be reported separately. Finally, preclinical 
toxicology studies did not support the testing of doses higher than 20 mg/kg in humans; 
therefore, although the maximum tolerable dose was not established, it is at least 20 
mg/kg/day. 
In conclusion, rifapentine, an antituberculosis drug with potential treatment-shortening 
properties, was tolerated by healthy adults at doses as high as 20 mg/kg/day. Average 
drug exposures were similar at the two highest doses tested. In humans, rifapentine is at 
least as strong a CYP3A inducer as rifampin when administered orally at the same mg/kg 
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dose. These results provide safety and tolerability data to support clinical trials of 
























Chapter 3 – Effects of HIV protease inhibitors lopinavir/ritonavir on the 
pharmacokinetics of CYP3A substrate drug quinine  
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The centuries-old antimalarial drug, quinine, continues to play a critical role in the 
treatment of severe falciparum malaria and uncomplicated malaria in pregnant women. It 
shares cytochrome P450 mediated metabolic pathways with several commonly used 
antiretroviral drugs, raising the potential for clinically important drug–drug interactions. 
A phase I pharmacokinetic study was conducted to assess the impact of long-term use of 
ritonavir-boosted lopinavir (LPV/r) on quinine pharmacokinetics in healthy volunteers. 
LPV/r significantly decreased the exposure of quinine and its major active metabolite, 3-
hydroxyquinine, in both total and free (unbound) forms. These findings highlight the 
complex nature of the influence exerted by LPV/r on several of the drug-metabolizing 
enzymes involved in quinine disposition, including CYP3A4, UDP-
glucuronosyltransferase, and P-glycoprotein. A decline in quinine exposure may 
compromise clinical efficacy. Further studies are warranted to assess changes in quinine 
pharmacokinetics and treatment outcomes in patients with acute malaria receiving 
antiretroviral therapy that includes LPV/r. 
Abbreviations 
AAG, α-1-acid glycoprotein; AUC, area under the plasma concentration-time curve; 
UGT, UDP- glucuronosyltransferase; P-gp, P-glycoprotein; PIs,  protease inhibitors; 
LPV/r, ritonavir-boosted lopinavir.  
Introduction 
The exaggerated burden of falciparum malaria in the presence of HIV is widely discussed 
in the literature and is best documented in individuals with limited or impaired immunity 
to malaria, such as pregnant women60. Concomitant use of antimalarial and antiretroviral 
drugs is becoming increasingly frequent in areas where malaria and HIV coexist, most 
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notably in many countries in sub-Saharan Africa. There is mounting evidence to suggest 
that clinically important pharmacokinetic interactions between these two classes of drugs 
may play a critical role in modifying the nature and degree of antimalarial drug exposure, 
safety, and efficacy61-63. 
Quinine is one of the most commonly used antimalarial drugs for the treatment of severe 
malaria as well as for the treatment of uncomplicated malaria in pregnancy. It is 
extensively metabolized, primarily by the hepatic CYP3A, to the major metabolite, 3-
hydroxyquinine64. This metabolite contributes 5–15% of antimalarial activity65. Both the 
parent drug and its metabolites are eliminated from the body through glucuronidation; up 
to 60% of the administered dose is recovered as urinary glucuronides and ~20–25% is 
excreted as unchanged quinine66. As with many CYP3A4 substrates, the P-glycoprotein 
(P-gp) drug transporter has also been implicated in quinine disposition67,68. Quinine is 
predominantly bound to α-1-acid glycoprotein (AAG)69,  a type 1 acute-phase protein that 
is upregulated during acute inflammatory states and infection, such as in untreated HIV70 
and malaria infection71. AAG binding to quinine is moderate in healthy individuals but 
may increase to > 90% in patients with acute malaria69.  
Ritonavir-boosted lopinavir (LPV/r) is a fixed-dose combination of HIV protease 
inhibitors that is commonly included in first-line HIV therapy regimens. Both compounds 
are primarily metabolized by the CYP3A family and bind to AAG with high affinity72. 
Ritonavir, best known for its potent inhibitory effects on CYP3A4 and CYP3A573,74, is 
now widely used to enhance the systemic bioavailability of other HIV protease inhibitors 
(PIs) such as lopinavir. However, ritonavir, alone or in combination with other PIs, also 
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exhibits a complex mixed inhibition–induction effect on several drug-metabolizing 
enzymes including, but not limited to, UDP-glucuronosyltransferases (UGTs)75 and 
membrane transporter P-gp76,77. Some of these activities of ritonavir result in a clinically 
important reduction in plasma drug concentrations75, raising concerns of a potential 
decline in therapeutic efficacy.  
Recently, a significant increase in quinine exposure was reported in healthy volunteers 
when quinine was coadministered with ritonavir78. Ritonavir's inhibition of CYP3A4 was 
thought to be responsible for this effect, and the investigators recommended a decrease in 
quinine dosing. However, ritonavir is essentially always used in combination with other 
protease inhibitors, often resulting in more complex CYP3A4- and UGT-related drug 
interactions. To our knowledge, there are no published data on the impact of LPV/r (the 
commonly used ritonavir/PI combination in current clinical practice) on the disposition of 
quinine. We conducted a phase I, two-phase, sequential-design pharmacokinetics study in 
healthy volunteers to assess the impact of LPV/r on quinine pharmacokinetics. 
Materials and Methods 
Reagents  
Quinine and its internal standard quinidine were obtained from Sigma-Aldrich (St. Louis, 
Missouri); and 3-hydroxyquine was from Toronto Research Chemicals Inc. (North York, 
Ontario, Canada). Their chemical structures are shown in Figure 3-1. Lopinavir, ritonavir, 
and their internal standard, A-86093.0, were obtained from Abbott Laboratories. High-
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performance liquid chromatography–grade methanol, acetonitrile, phosphoric acid, 


















Figure 3-1. Chemical structures of 3-hydroxyquinine, quinine and the internal 














Study design  
A phase I, single-center, open-label, sequential pharmacokinetics study was conducted to 
assess the impact of LPV/r on the pharmacokinetics of quinine in healthy volunteers. The 
study was reviewed and approved by the institutional review board of Johns Hopkins 
Medical Institutions and was conducted in compliance with national and local 
institutional guidelines. 
Participants  
Inclusion criteria included age 18–55 years, body mass index 18–32 kg/m2, no evidence 
of medical illness on the comprehensive history and physical examination, normal 
readings on the 12-lead EKG, and normal laboratory test values (complete blood count, 
blood chemistry (Chem12), including serum electrolytes, hepatic enzymes, serum 
creatinine, pancreatic enzymes, G6PD, HIV and hepatitis panel, coagulation factors, and 
lipid profile). All participants gave consent in writing. Any prescribed or over-the-
counter medications, alcohol, tobacco, and any food or beverage containing substances 
known or suspected to interact with the CYP3A family were prohibited for 2 weeks prior 
to and during the study. Premenopausal women were required to have a negative 
pregnancy test and use two methods of nonhormonal contraception. The participants were 
admitted as inpatients on study days 0–4 and days 14–15 and monitored in an outpatient 
setting on days 8, 10, 12, 18, 29, and as clinically indicated. 




The participants received a single oral dose of quinine sulfate 648 mg (538 mg base) on 
study days 1 and 15, a single oral dose of LPV/r (400/100 mg) on day 4, and LPV/r twice 
a day on days 5–17 (inclusive). Quinine sulfate was purchased from Ar Scientific 
(Philadelphia, PA) and was manufactured for Mutual Pharmaceutical (Philadelphia, PA). 
LPV/r was purchased from Abbott Laboratories (Abbott Park, IL) via the Johns Hopkins 
Investigational Drug Service. 
The participants fasted overnight and up to 4 h after drug administration on study days 1 
and 15. Quinine and the first dose of LPV/r were administered with 8 oz of water under 
direct supervision. The time points for venous blood collection for the pharmacokinetics 
analysis were as follows: for quinine, within 15 min before the dose (pre-dose) and at 0.5, 
1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 h after the dose on study days 1 and 15; for LPV/r, pre-
dose, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h after the dose on day 4; predose, 0.5, 1, 2, 3, 
4, 6, 8, and 12 h after the dose on day 15; and before the morning doses on days 8, 10, 12, 
and 14. Blood was collected in a vacutainer containing sodium heparin. Plasma was 
separated by centrifugation (1,500 × g for 10 min at 4 °C) within 30 min of collection and 
stored at −80 °C until analysis. 
Measurement of plasma concentrations of drugs and their metabolites 
Concentrations of quinine/3-hydroxyquinine in plasma were determined using a validated 
high-performance liquid chromatography method with fluorescent detection, using 
modifications to a previously reported method79. To obtain protein-bound free quinine/3-
hydroxyquinine,  1 ml of plasma samples were equilibrated for 30 min at 37°C and 
transferred to Amicon Centrifree filters (30,000 MWCO; Millipore, Billerica, MA)80 
66 
 
followed by ultrafiltration at the same temperature in a fixed angle rotor centrifuge at 
1000 × g for 10 min. A volume of 300 μL of the ultrafiltrates was then assayed for free 
drug concentration determination.  
A protein precipitation technique was used in the preparation of calibrators, QCs, the 
unknown plasma samples and the ultrafiltrates from human subjects. Plasma or filtrate, 
calibrators, or QCs (300 µl) were put into 12 × 75 mm glass tubes; and 100 µl of the 
internal standard solution (1 µg/ml quinidine in methanol) were added and mixed. Then 
800 µl of methanol were added and vortexed for 10 s followed by centrifugation at 3000 
× g for 10 min. Supernatants were transferred to a new tube, dried in SpeedVac (Thermo 
Electron Corp., San Jose, CA) at 75°C for 2 h and reconstituted in 250 µl of mobile phase 
A (water/triethylamine (99:1, v/v) at pH 2.5 adjusted with phosphoric acid). The samples 
were transferred and 200 µl of samples were injected into a Ultrasphere C18 ODS 4.6 × 
250 mm (5 µm particle size) column with a responding guard cartridge (7.5 × 4.6 mm, 
5µm particle size) (Beckman, Brea, California). Mobile phase B was acetonitrile/ 
triethylamine (99:1, v/v). The program for the gradient mobile phase is shown as Table 
3-1. The flow rate was 1.5 ml/min. Acquisition of chromatographic data was obtained 
using Waters 2695 high performance liquid chromatography (HPLC) system with a 
Waters 474 fluorescence detector interfaced with Waters Empower 2 software (Milford, 
Massachusetts). Fluorescence detection was performed at 350 nm (excitation) and 450 
nm (emission). The HPLC analysis was conducted at room temperature. The 
concentrations of quinine and 3-hydroxyquinine were determined from calibration plots 
of the chromatographic peak height ratios to that of quinidine versus concentration.  
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Measurements of lopinavir and ritonavir were performed using a validated HPLC method 
conjugated with ultraviolet detection, as previously reported81. The linear range was 100–
15,000 ng/ml for both lopinavir and ritonavir. 
Pharmacokinetic and statistical data analyses 
Data were double key–entered into Microsoft Excel (Microsoft Office Professional, 
Microsoft, Redmond, WA). Pharmacokinetic parameters were estimated using 
noncompartmental methods (WinNonlin Professional, version 5.3, Pharsight, Mountain 
View, CA). Statistical analyses were performed using Stata (version 10.0; Stata, College 
Station, TX). Because the continuous data were skewed, medians and IQRs were used to 
summarize the data. The Wilcoxon signed-rank test was used to test the statistical 
significance of differences in the pharmacokinetic parameters between test conditions. 
The geometric mean ratio and 90% confidence interval were used to describe the ratio of 
the pharmacokinetics of quinine plus LPV/r to that of quinine alone. Random-effects 
models were used to evaluate the attainment of steady state for lopinavir and ritonavir82. 
The estimated coefficient of time (slope) was interpreted as the rate of change in log–
plasma trough concentrations over time, where time is a predictor of change. Sample size 
was selected based on the intra-individual coefficient of variation of quinine area under 
the plasma concentration-time curve (AUC) observed in a ketoconazole interaction 
study83; the sample size was selected to detect at least a 35% difference (with a 5% type I 






Table 3-1. The program of the gradient mobile phase of HPLC assay. 
 
 
Time (min) A% B% 
0.0 96 4 
0.1 94 6 
1.1 92 8 
14.0 92 8 
14.5 20 80 
17.5 20 80 
















An assay was developed and validated for simultaneous determination of plasma quinine 
and 3-hydroxyquinine. Under the chromatographic conditions, the two analytes were well 
separated from the internal standard, quinidine (Figure 3-2). LPV and RTV did not affect 
the fluorescence signal of quinine and 3-hydroxyquinine (data not shown). The retention 
times for 3-hydroxyquinine, quinidine and quinine were 5.0 min, 12.4 min and 14.8 min, 
respectively (Figure 3-2). The lower limits of quantification (LLOQs) for quinine and 3-
hydroxyquinine were 30 and 20 ng/ml, respectively. The linear ranges for quinine and 3-
hydroxyquinine were 30-5000 ng/ml and 20-5000 ng/ml, respectively. The representative 
calibration curves are shown in Figure 3-3.  
The intra-run coefficient of variation and accuracy of quality controls ranged from 1.3 to 
9.5% and −4.7 to 7.1%, respectively, for quinine (Table 3-2), and from 1.2 to 6.0% and 
−6.0 to 5.4%, respectively, for 3-hydroxyquinine (Table 3-3). The inter-run coefficient of 
variation and accuracy of quality controls ranged from 2.6 to 5.3% and −1.6 to 1.8%, 
respectively, for quinine, and from 4.0 to 4.1% and −1.8 to 0.6%, respectively, for 3-
hydroxyquinine. Stability tests showed that quinine and 3-hydroxyquinine were stable at 
room temperature in both plasma and injection matrix for 3 days; and they were stable 
through 3 freeze-thaw cycles. The recovery of quinine, 3-hydroxy quinine and the 
internal standard for the extraction method was ≥ 79 %. For partial volume validation 
test, quinine had precisions of ≤ 4.8 % and accuracies of within ± 10.3 % for all sample 
dilutions (Table 3-4); and 3-hydroxyquinine had precisions of ≤ 5.3 % and accuracies of 
within ± 7.3 % (Table 3-5). 
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Figure 3-2. HPLC chromatogram of quinine and 3-hydroxyquinine and the internal 
standard, quinidine. Human plasma (300 µl) was spiked with 250 ng/mL of QN and 3-
OHQN. One hundred µl of 1000 ng/mL quinidine were added and mixed followed by 
extraction. The retention time of drugs in minutes were labeled on the top of relative 












Figure 3-3. Representative calibration curves. Top and bottom panels are quinine 
(QN) and 3-hydroxyqinine (3-OHQN), respectively. The y-axis is the peak height ratio of 
analyte to the internal standard, quinidine. Equations and values of r2 for linear regression 







Table 3-2.  Stability, recovery, accuracy, and precision of quinine. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 30 90 250 4,000 
Freeze-Thaw* (% change) N 0.3 N 0.8 
Stability† (% change) N -3.3 N -0.1 
Recovery (%) N 79 N 81 
Intra-run Precision‡ (ranges of CV) 4.6-10 1.9-9.5 1.8-3.4 1.3-2.6 
Intra-run Accuracy‡ (ranges, %) -6.6-15 -4.7-0.7 -1.9-7.1 -1.4-3.5 
Inter-run Precision‡ (CV) 9.1 4.1 4.0 4.0 
Inter-run Accuracy‡ (%) 4.1 -1.6 1.8 1.4 
Injection Matrix Stability# N 1.7 N 0.8 
 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*3 cycles; N = not determined 
†Room temperature for 3 days 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 







Table 3-3. Partial volume validation results of quinine.  
 Medium QC High QC 3 × ULOQ 




270 277 3968 4152 16148 16723 15504 
269 261 4039 4131 16286 16470 15649 
267 252 4036 4250 16341 16458 15562 
Theoretical Value 
(ng/mL) 
250 250 4000 4000 15000 15000 15000 
Mean (ng/mL) 269 263 4015 4178 16259 16550 15572 
SD 1 13 40 64 100 150 73 
% CV 0.5 4.8 1.0 1.5 0.6 0.9 0.5 
% Dev 7.5 5.2 0.4 4.4 8.4 10.3 3.8 














Table 3-4.  Stability, recovery, accuracy, and precision of 3-hydroxyquinine. 
 
Items LLOQ Low Med High 
Concentrations (ng/ml) 20 60 250 4,000 
Freeze-Thaw* (% change) N 1.1 N -0.9 
Stability† (% change) N 9.3 N 1.4 
Recovery (%) N 86 N 80 
Accuracy‡ (%) 1.1 -1.6 0.6 -1.8 
Intra-run Precision‡ (ranges of CV) 4.0-9.0 3.2-6.0 1.2-3.5 1.9-4.3 
Inter-run Precision‡ (CV) 13 8.2 6.6 6.4 
Injection Matrix Stability# N -1.2 N -4.2 
 
Abbreviations: LLOQ = Lowest Limit of Quantitation; Low = Low Quality Control; Med = Medium 
Quality Control; High = High Quality Control 
*3 cycles; N = not determined 
†Room temperature for 3 days 
‡From 5 independent runs with 6 replicates per run of each quality control concentration 








Table 3-5. Partial volume validation results of 3-hydroxyquinine.  
 Medium QC High QC 3 × ULOQ 




258 277 4100 4268 15785 16273 15409 
255 259 4222 4266 15838 15918 15480 
278 250 4201 4331 15742 16036 15490 
Theoretical Value 
(ng/mL) 
250 250 4000 4000 15000 15000 15000 
Mean (ng/mL) 264 262 4174 4288 15788 16076 15460 
SD 13 14 65 37 48 181 44 
% CV 4.8 5.3 1.6 0.9 0.3 1.1 0.3 
% Dev 5.5 4.7 4.4 7.2 5.3 7.3 3.1 









Pharmacokinetics of quinine and its major active metabolite 3-hydroxyquinine 
In the presence of steady-state LPV/r, plasma concentrations decreased for both quinine 
(Figure 3-4) and 3-hydroxyquinine (Figure 3-5) compared with those when quinine was 
administrated alone. The changes in protein-bound free concentrations followed the same 
pattern. The maximal concentration (Cmax) and the total drug exposure measured as the 
area under the plasma concentration–time curve extrapolated to infinity (AUC0–inf) 
decreased both for quinine (48% and 50% reduction in total quinine Cmax and AUC0–inf, 
respectively, Table 3-6) and for 3-hydroxyquinine (69% reduction in both total 3-
hydroxyquinine Cmax and AUC0–inf) (Table 3-7). The concentrations of the drug and its 
metabolite in plasma at 8 h after dosing (8 h being the time at which trough concentration 
is reached after dosing in the standard malaria treatment) were also reduced (45% for 
total quinine and 67% for 3-hydroxyquinine). Both total clearance and apparent volume 
of distribution increased, with the extent of increase being larger for total clearance than 
for apparent volume of distribution, resulting in a decrease in the terminal half-life. 
However, this decline in half-life was not statistically significant either for total quinine 
or for total 3-hydroxyquinine. The change in free quinine (Table 3-8) and free 3-
hydroxyquinine (Table 3-9) concentrations was statistically significant for all 
pharmacokinetic parameters measured, although slightly smaller in magnitude than for 





Figure 3-4. Plasma concentration-time profiles. Top and bottom panels are for quinine 
and 3-hydroxyqinine, respectively. Solid lines represent quinine alone; broken lines 
represent quinine plus LPV/r. Plots with filled circles represent total drug concentrations, 
















Table 3-6. Pharmacokinetic parameters of total quinine when quinine was 
administered alone and in the presence of steady-state LPV/r. 
AUC0–inf, area under the plasma concentration–time curve extrapolated to infinity; C8, plasma 
concentration at 8 h after quinine administration, representing the end of a dosing interval in standard 
malaria treatment; CI, confidence interval; CL/F, apparent clearance; Cmax, maximal concentration; GMR–
tQN, geometric mean ratio of total quinine in presence of LPV/r to administration of quinine alone; LPV/r, 
ritonavir-boosted lopinavir; PK, pharmacokinetic; Tmax, time to Cmax; T1/2, terminal elimination half-life; 
V/F apparent volume of distribution. 















Tmax (h) 3.0 (3.0–3.0) 3.0 (3.0–3.3) 1.09 (0.86–1.40) 0.39 
Cmax (mg/L) 3.2 (2.5–3.7) 1.5 (1.3–2.0) 0.52 (0.44–0.61) 0.001 
AUC0-inf (mg·h/L) 46.7 (41.1–79.2) 24.6 (22.0–30.1) 0.50 (0.39–0.64) 0.0003 
T1/2 (h) 13.7 (11.1–15.8) 10.4 (7.4–14.0) 0.84 (0.71–1.0) 0.192 
V/F (L) 184 (131–272) 316 (272–430) 1.68 (1.37–2.07) 0.0023 
CL/F (L/h) 11.5 (6.8–13.1) 22.0 (17.9–24.5) 2.0 (1.56–2.57) 0.0003 
C8 (mg/L) 2.0 (1.6–2.5) 1.12 (0.91–1.30) 0.55 (0.45–0.67) 0.0003 
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Table 3-7. Pharmacokinetic parameters of total 3-hydroxyquinine when quinine was 
administered alone and in the presence of steady-state LPV/r.  
PK parameter 





(N = 13) 
With LPV/r  
(N = 12) 
Tmax (h) 3.0 (2.0–3.0) 3.0 (3.0–3.3) 1.26 (0.94–1.69) 0.083 
Cmax (mg/L) 0.40 (0.29–0.52) 0.13 (0.10–0.22) 0.31 (0.25–0.38) 0.0001 
AUC0-inf (mg·h/L) 6.3 (6.1–9.0) 2.0 (1.6–3.2) 0.31 (0.27–0.35) 0.0001 
T1/2 (h) 11.9 (11.0–16.4) 10.6 (8.8–13.6) 0.87 (0.76–1.0) 0.174 
V/F (L) 1474 (939–1944) 3610(2702–4862) 2.86(2.39–3.42) 0.0002 
CL/F (L/h) 85.8 (59.6–88.6) 275 (167–338) 3.27 (2.88–3.70) 0.0001 
C8 (mg/L) 0.25 (0.19–0.32) 0.18 (0.17–0.19) 0.72 (0.59–0.87) 0.0039 
AUC0–inf, area under the plasma concentration–time curve extrapolated to infinity; C8, plasma 
concentration at 8 h after quinine administration, representing the end of a dosing interval in standard 
malaria treatment; CI, confidence interval; CL/F, apparent clearance; Cmax, maximal concentration; GMR–
t3OH, geometric mean ratio of total 3-hydroxyquinine in presence of LPV/r to administration of quinine 
alone; LPV/r, ritonavir-boosted lopinavir; PK, pharmacokinetic; Tmax, time to Cmax; T1/2, terminal 
elimination half-life; V/F apparent volume of distribution. 









Table 3-8. Pharmacokinetic parameters of free quinine when quinine was 
administered alone and in the presence of steady-state LPV/r. 
AUC0–inf, area under the plasma concentration–time curve extrapolated to infinity; C8, plasma 
concentration at 8 h after quinine administration, representing the end of a dosing interval in standard 
malaria treatment; CI, confidence interval; CL/F, apparent clearance; Cmax, maximal concentration; GMR–
fQN, geometric mean ratio of free quinine in presence of LPV/r to administration of quinine alone; LPV/r, 
ritonavir-boosted lopinavir; PK, pharmacokinetic; Tmax, time to Cmax; T1/2, terminal elimination half-life; 
V/F apparent volume of distribution. 















Tmax (h) 3.0 (3.0–3.0) 3.0 (3.0–3.0) 1.06 (0.95–1.19) 0.513 
Cmax (mg/L) 0.38 (0.36–0.51) 0.26 (0.24–0.31) 0.67 (0.57–0.78) 0.0013 
AUC0-inf (mg·h/L) 5.0 (4.4–8.9) 3.7 (3.1–4.0) 0.64 (0.49–0.85) 0.0019 
T1/2 (h) 9.4 (8.4–13.7) 8.1 (5.8–9.7) 0.80 (0.66–0.96) 0.103 
V/F (L) 1345 (1063–1655) 1752(1513–1974) 1.24 (1.06–1.45) 0.064 
CL/F (L/h) 108 (60.4–122) 146 (134–175) 1.55 (1.18–2.04) 0.0019 
C8 (mg/L) 0.27 (0.19–0.36) 0.10 (0.07–0.15) 0.33 (0.28–0.39) 0.0001 
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Table 3-9. Pharmacokinetic parameters of free 3-hydroxyquinine when quinine was 
administered alone and in the presence of steady-state LPV/r. 
AUC0–inf, area under the plasma concentration–time curve extrapolated to infinity; C8, plasma 
concentration at 8 h after quinine administration, representing the end of a dosing interval in standard 
malaria treatment; CI, confidence interval; CL/F, apparent clearance; Cmax, maximal concentration; GMR–
f3OH, geometric mean ratio of free 3-hydroxyquinine in presence of LPV/r to administration of quinine 
alone; LPV/r, ritonavir-boosted lopinavir; PK, pharmacokinetic; Tmax, time to Cmax; T1/2, terminal 
elimination half-life; V/F apparent volume of distribution. 









GMR – f3OH 
(95% CI) 
p-value Alone 
(N = 13) 
With LPV/r 
(N = 12) 
Tmax (h) 3.0 (2.0–3.0) 3.0 (3.0–3.0) 1.2 (1.0–1.4) 0.0399 
Cmax (mg/L) 0.24 (0.17–0.29) 0.10 (0.08–0.15) 0.41 (0.35–0.48) 0.0007 
AUC0-inf (mg·h/L) 4.3 (3.5–5.1) 1.9 (1.1–2.2) 0.35 (0.29–0.43) 0.0001 
T1/2 (h) 12.6 (10.8–17.6) 8.0 (7.5–12.5) 0.71 (0.62–0.82) 0.0743 
V/F (L) 2794(1592–3135) 4995 (3678–6167) 2.03 (1.71–2.41) 0.0081 
CL/F (L/h) 125 (105–154) 281 (243–483) 2.85 (2.33–3.50) 0.0001 
C8 (mg/L) 0.15 (0.12–0.20) 0.06 (0.05–0.09) 0.43 (0.37–0.50) 0.0007 
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The median (IQR) of the ratio of the AUCs of total 3-hydroxyquinine to total quinine was 
0.14 (0.10–0.18) when quinine was administered alone. The ratio decreased to 0.07 
(0.05–0.13) when quinine was coadministered with LPV/r (p = 0.033 per Wilcoxon 
signed-rank test). The ratio of the AUCs of free 3-hydroxyquinine AUC to free quinine 
was 0.53 (0.45–0.64) when quinine was administered alone, and the ratio decreased to 
0.36 (0.27–0.52) in the presence of LPV/r (p = 0.0076). The free fraction of quinine 
(median (IQR)) represented ~10.8% (9.2–12.4%) of total quinine when quinine was 
administered alone, and it increased to 15.6% (12.6–17.7%) when quinine was 
coadministered with LPV/r (p = 0.0047). The free fraction of 3-hydroxyquinine did not 
change in the presence of LPV/r. 
Pharmacokinetics of lopinavir and ritonavir 
Single-dose and steady-state pharmacokinetics estimates of lopinavir and ritonavir are 
shown in Table 3-10 and Table 3-11, respectively. A steady-state concentration seemed 
to be reached by study days 8 and 10 for ritonavir and lopinavir, respectively (Figure 3-
5). The total exposure (median (IQR)) of lopinavir and ritonavir when LPV/r was 
administered alone were not significantly different from the levels when LPV/r was 
administered with quinine: lopinavir AUC0–inf 76.4 mg·h/L (55.4–114 mg·h/L) and 
AUC0–tau 93.4 mg·h/L (77.9–120 mg·h/L) (p = 0.39); ritonavir AUC0–inf 3.4 mg·h/L (3.1–





Table 3-10. Pharmacokinetic parameters of lopinavir following a single oral dose of 













Values expressed in median (interquartile range). 
AUC, area under the plasma concentration–time curve; CL/F, apparent clearance; Cmax, maximal 
concentration; Cmin, minimal concentration; LPV/r, ritonavir-boosted lopinavir; N/A, not determined; PK, 
pharmacokinetic; Tmax, time to Cmax; T1/2, terminal elimination half-life; V/F, apparent volume of 
distribution. 
*Steady-state pharmacokinetic parameters following twice daily dosing of LPV/r in the presence of quinine. 
†For single dose, AUC extrapolated to infinity (AUC0-inf); for steady-state, AUC are calculated during a 
















Tmax (h) 3.0 (3.0 – 6.0) 2.0 (2.0 – 3.3) 
Cmax (mg/L) 6.2 (4.3 – 7.7) 10.2 (8.0 – 13.3) 
Cmin (mg/L) N/A 4.7 (4.1 – 6.2) 
AUC(mg·h/L)† 76.4 (55.4 – 114) 93.4 (77.9 – 120) 
T1/2 (h) 6.0 (5.3 – 7.5) 9.9 (7.8 – 11.4) 
V/F (L) 45.7 (42.3 – 56.2) 60.1 (48.7 – 75.5) 
CL/F (L/h) 5.23 (3.5 – 7.2) 4.3 (3.4 – 5.1) 
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Table 3-11. Pharmacokinetic parameters of ritonavir following a single oral dose of 













Values expressed in median (interquartile range). 
AUC, area under the plasma concentration–time curve; CL/F, apparent clearance; Cmax, maximal 
concentration; Cmin, minimal concentration; LPV/r, ritonavir-boosted lopinavir; N/A, not determined; PK, 
pharmacokinetic; Tmax, time to Cmax; T1/2, terminal elimination half-life; V/F, apparent volume of 
distribution. 
*Steady-state pharmacokinetic parameters following twice daily dosing of LPV/r in the presence of quinine.  
†For single dose, AUC extrapolated to infinity (AUC0-inf); for steady-state, AUC are calculated during a 








(N = 13) 
Steady-state* 
(N = 12) 
Tmax (h) 4.0 (3.0 – 6.0) 2.0 (2.0 – 3.5) 
Cmax (mg/L) 0.33 (0.24 – 0.45) 1.1 (0.8 – 1.3) 
Cmin (mg/L) N/A 0.18 (0.12 – 0.24) 
AUC(mg·h/L)† 3.4 (3.1 – 5.9) 6.1 (5.0 – 8.3) 
T1/2 (h) 5.8 (4.9 – 8.0) 4.2 (3.7 – 4.7) 
V/F (L) 221 (174 - 256) 98.4 (73.8 – 131)  
CL/F (L/h) 29.5 (17.5 – 32.8) 16.4 (12.1 – 20.1) 
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Figure 3-5. Trough plasma concentrations of lopinavir (solid line) and ritonavir 
(broken line) after twice-daily administration of ritonavir-boosted lopinavir (LPV/r) 


















Quinine is the oldest and probably the best characterized antimalarial drug in terms of its 
pharmacokinetics and pharmacodynamics. Unlike other antimalarial drugs, quinine has a 
relatively well defined therapeutic range of total quinine plasma trough concentration (5–
15 mg/L). There is considerable overlap of the therapeutic and toxic concentrations for 
quinine. At about 5 mg/L, the notorious adverse effects of quinine, including the signs 
and symptoms of cinchonism84, usually appear, with the result that successful therapy 
with quinine is almost always associated with some degree of noxious adverse effects85. 
Despite its record of poor tolerability, quinine maintains its critical role in malaria 
treatment because of its persistent efficacy against Plasmodium falciparum that has 
evolved resistance to most other drugs and also because of its reasonable safety profile, 
low cost, long shelf life, and wide availability. It is also the only antimalarial drug known 
to be safe in early pregnancy and widely available worldwide for parenteral use in the 
treatment of severe malaria. Quinine may be increasingly relied on if the recently 
emergent artemisinin resistance in Southeast Asia86 disseminates more widely. 
LPV/r is the most commonly used ritonavir-based combination in HIV management87. 
Our study showed that co-administration of LPV/r caused a significant decrease in 
exposure of both quinine and its active metabolite, 3-hydroxyquinine. This contrasts with 
a recent finding by Soyinka et al. of a large increase in quinine concentrations when 
quinine was administered along with ritonavir78. The authors concluded that potent 
inhibition of CYP3A4 by ritonavir was responsible for the increase in quinine exposure, 
and they recommended reducing quinine dosing in the presence of ritonavir. However, 
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the recommendation for quinine dose reduction on the basis of evaluation of ritonavir 
alone may be premature. The design of our study differed from that of the study by 
Soyinka et al. with respect to two important factors: (i) our study assessed the impact of 
ritonavir plus lopinavir on quinine pharmacokinetics, whereas Soyinka and colleagues’ 
study evaluated ritonavir alone, and (ii) our study participants received LPV/r containing 
200 mg ritonavir per day for 10 days before the second round of quinine administration, 
whereas the participants in the study by Soyinka et al. received higher doses of ritonavir 
(400 mg/day) for a shorter duration (6 days). One partial explanation for the differences 
in study findings could be that the findings by Soyinka et al. are the result of dominant 
CYP3A4 inhibition before induction was complete. The availability of metabolite and 
free drug concentration data in our study allowed exploration of additional mechanisms 
of drug interaction apart from CYP3A4 inhibition, possibly involving multiple drug-
metabolizing enzymes and drug transporters including, but not limited to, phase II 
enzyme UGT and P-gp. 
We found that the metabolic ratio of 3-hydroxyquinine to quinine was reduced by ~50% 
in the presence of LPV/r, consistent with ritonavir's potent inhibitory action on CYP3A4. 
In the presence of CYP3A4 inhibition, one would expect the exposure of the parent drug, 
quinine, to be increased. However, our study showed the opposite result. The exposure of 
both quinine and 3-hydroxyquinine were significantly decreased, and the decrease was 
greater for 3-hydroxyquinine (Figure 3-4). There was also an associated large increase in 
apparent distribution and total clearance for both compounds and a decrease in half-life, 
possibly indicating a decline in bioavailability secondary to increased pre-systemic 
metabolism induced by ritonavir. In the presence of other protease inhibitors, ritonavir 
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can also exhibit a mixed inhibition-inducing effect on several drug-metabolizing enzymes, 
in addition to CYP3A4. This inductive effect has been shown to reduce the exposure of 
several drugs, resulting in recommendations for dose adjustment or alternative therapy75. 
One of these ritonavir-induced enzymes, UGT, is also responsible for the final 
conjugation of quinine and 3-hydroxyquinine. Although the family or subfamily of UGTs 
involved in the disposition of quinine and 3-hydroxyquinine have not been clearly 
identified, it has been shown that up to 60% of the administered dose of quinine is 
recovered as glucuronides and 20–25% as unchanged quinine. We suspect that the 
significant reductions in quinine and 3-hydroxyquinine were mediated by the induction of 
UGT. A decrease in the rate of formation (because of inhibition of CYP3A4) and an 
increase in the metabolism of 3-hydroxyquinine (because of induction of UGTs) may 
account for the observed greater reduction in concentrations of 3-hydroxyquinine than in 
those of quinine. 
Another potential pathway that may be involved in the quinine-LPV/r interaction is P-gp 
multidrug efflux transporter. Many substrates of CYP3A4, like quinine, are known to be 
substrates of P-gp as well88, and P-gp is known to be induced by chronic administration 
of ritonavir77. The two-fold reduction in quinine concentration despite ritonavir-mediated 
CYP3A4 inhibition may reflect simultaneous induction of UGTs and P-gp, resulting in an 
increased intestinal drug efflux and presystemic metabolism leading to reduced 
bioavailability. Lopinavir is unlikely to be the cause of this suspected induction because it 
does not have inductive effects89.  
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The 50% increase in the free fraction of quinine in the presence of LPV/r may have also 
enhanced the availability of quinine for enzymatic biotransformation and increased the 
volume of distribution. The reason for this increase is unclear. HIV protease inhibitors 
bind to AAG with high affinity72, whereas quinine binding to AAG is moderate in 
healthy volunteers69. Although displacement of quinine from AAG by lopinavir and 
ritonavir is a possible explanation, it is unlikely that this change in protein binding would 
have caused a significant impact on the overall quinine exposure or had an important 
clinical implication. This is because the quinine was orally administered and has a 
relatively small hepatic extraction90.  
Adverse events were frequent in our study. Symptoms suggestive of quinine-induced 
cinchonism (headache, nausea, and tinnitus) occurred in 13% of the participants, and 
gastrointestinal discomfort, probably associated with LPV/r, was found in >70% of the 
participants. The nature of the adverse events and their frequency were similar to 
previous observations91-93. A significant QTc prolongation, which is likely to be 
associated with quinine treatment, was found in the two female participants who received 
the two highest quinine doses on a per kilogram basis. The drug concentrations in these 
participants were not different from those in the others, and therefore there was no 
evidence of a concentration–response relationship. Although the absolute length of the 
QTc interval did not exceed 500 ms, the maximal increase of > 60 ms from baseline 
raised a clinical concern. Changes of similar magnitude in the QT interval in association 
with quinine treatment have been reported in healthy volunteers94-96. Cardiac toxicity 
seems to be more frequent in healthy volunteers than in patients with acute malaria97, and 
this raised a caution for the drug cocktail studies wherein quinine is commonly used to 
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probe CYP3A494-96. It is also known that the baseline QT interval determines the risk of 
arrhythmia98; women have longer baseline QT intervals and are therefore at greater risk 
for drug-induced torsade de pointes99,100. A larger study is needed to assess the risk of 
quinine-related cardiac toxicity in women of reproductive age, the population most likely 
to be exposed to this drug in malaria-endemic countries. 
One of the female participants in our study who developed QTc prolongation also 
developed a skin exanthema when both quinine and LPV/r were present; this made it 
impossible to identify the likely cause clearly. As stated earlier, quinine exposure in this 
participant did not differ from those in other participants, suggesting that 
pharmacokinetic polymorphisms were not involved. Dermatologic adverse effects have 
been reported in association with either quinine hypersensitivity reaction91 or LPV/r101; 
however, the dermatologic adverse effects are believed to be uncommon with either 
drug92,93. Given the Asian ancestry of this research participant, it is worth considering the 
Stevens-Johnson syndrome. This syndrome has been attributed to treatment with 
carbamazepine102 and allopurinol103 in the presence of human leukocyte antigen 
polymorphisms HLA-B*1502 and HLA-B*5801, respectively, in Han Chinese. 
The major limitation of our study is that only a single dose of quinine was tested in 
healthy volunteers. A healthy population enables us to avoid the potential impact of 
illness and minimize the complexity associated with the concomitant use of multiple 
drugs that is typically prevalent in the HIV-infected patient population. The nature and 
degree of drug interactions observed in healthy volunteers are usually similar to 
interactions seen in HIV-infected populations104,105, and findings in healthy volunteers are 
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generally being applied to individuals with HIV. However, the recent discovery of a 
striking discordance in results between a study in healthy volunteers106 and one in 
patients with HIV and tuberculosis107 suggests caution in extrapolating findings in 
healthy volunteers to populations with disease. Confirmatory studies in relevant target 
populations should be encouraged108. It is also plausible that quinine disposition could 
differ between healthy and malaria-infected populations because of important differences 
that may influence quinine metabolism, including the abundance of the major drug-
binding protein AAG and underlying hepatic and renal functions. Similarly, the impact of 
LPV/r may be different after a single quinine dose than after multiple quinine doses (as 
are typically encountered in treatment regimens). For these reasons, our findings should 
be confirmed in patients coinfected with malaria and HIV. In addition, the metabolic 
pathways proposed to explain quinine disposition in our study are conjectural; the 
assessment of glucuronides and other metabolic products should be carried out for a full 
understanding of the interaction between quinine and LPV/r. 
Conclusions 
The HIV protease inhibitor combination LPV/r causes a significant decline in exposure 
(Cmax and AUC) of quinine and its major active metabolite, 3-hydroxyquinine, after a 
single oral dose of 538 mg base quinine in healthy volunteers. This decline was noted in 
both the total and free forms of the quinine and its metabolite, and the degree of reduction 
was larger for the metabolite than for the parent drug. In the presence of steady-state 
LPV/r, the metabolic ratio of 3-hydroxyquinine to quinine decreased, and the free 
fraction of quinine (but not 3-hydroxyquinine) increased. A single dose of quinine did not 
affect the total exposure of either lopinavir or ritonavir. Because quinine is efficacious 
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within a relatively narrow concentration range, a routine quinine regimen in individuals 
who are also taking long-term LPV/r-based antiretroviral treatment may not achieve 
therapeutic quinine concentrations, thereby compromising the efficacy of the malaria 
treatment. A careful assessment of quinine pharmacokinetics in association with 
antimalarial treatment outcomes is needed in a relevant population of individuals living 
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Maraviroc is an anti-HIV drug that acts by blocking viral entry into target cells. Using 
ultra performance liquid chromatography-mass spectrometry several monooxygenated, 
dioxygenated and glucuronidated metabolites of maraviroc were identified both in vitro 
and in vivo. Characterization of the enzymes involved in the production of these 
metabolites determined that CYP3A5 was the principal enzyme responsible for the 
formation of an abundant metabolite of maraviroc that resulted from oxygenation of the 
dichlorocyclohexane ring. For the formation of this metabolite the Vmax values for 
CYP3A4 and CYP3A5 were 0.04 and 0.93 pmole/min/pmole P450, and the Km values 
were 11.1 μM and 48.9 μM, respectively. Further, human liver microsomes isolated from 
donors homozygous for the loss-of-function CYP3A5*3 allele exhibited a 79% decrease 
in formation of this metabolite as compared to those homozygous for the wild-type 
CYP3A5*1 allele. In order to probe which divergent residues between CYP3A4 and 
CYP3A5 might play a role in the differential activities of these enzymes towards 
maraviroc mutations were introduced into both enzymes and metabolism of maraviroc 
was measured. A CYP3A5 L57F mutant exhibited a 61% decrease in the formation of 
this metabolite whereas formation by a CYP3A4 F57L mutant was increased by 337% as 
compared to wild-type. Taken together, these data provide novel insight into the 
biotransformation of maraviroc as well as the potential role of CYP3A4 and CYP3A5 
divergent residues in the enzymatic activities of these two highly homologous enzymes. 
Abbreviations 
CYP, a cytochrome P450; UPLC-MS, ultra performance liquid chromatography-mass 
spectrometry; SRSs, substrate recognition sites; UDP-glucuronosyltransferase, UGT; 
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UDPGA, uridine disphosphoglucuronic acid. 
Introduction 
The cytochromes P450s are a superfamily of heme-containing monooxygenases that play 
a crucial role in drug clearance. The CYP3A subfamily enzymes CYP3A4 and CYP3A5 
are responsible for the metabolism of more than 50% of drugs currently on the market 109. 
They share 84% amino acid sequence identity and 92% similarity resulting in 
overlapping substrate specificities9. As such, defining their respective contributions to 
drug metabolism as well as drug-drug interactions remains challenging. It is well 
established that CYP3A5 is polymorphically expressed with the wild type CYP3A5*1 
allele being associated with the highest amount of protein expression whereas variant 
alleles such as CYP3A5*3 lead to decreased expression or no activity due to alternative 
mRNA splicing 15,16. In individuals that carry at least one CYP3A5*1 allele, CYP3A5 
protein accounts for at least 50% of the total hepatic CYP3A content 15. The expression 
of CYP3A5 is highly variable among different ethnic populations. For instance, the 
CYP3A5*3 allele is abundantly present in the European American population with a 
frequency of 85-98% while it is much less common in the African American population 
with a frequency of 27-48% 15,16,18,20. In addition, increased risk of certain drug toxicities 
has been reported in people who have low expression of CYP3A5 24-26.   
To date, several CYP3A4 crystal structures have been solved while the structure of 
CYP3A5 is not yet available. Six CYP3A4 substrate recognition sites (SRS1-6) were 
identified and experimentally demonstrated to be important for substrate binding and 
catalytic activity 110-116.  Phenylalanine residues F108, F213, F215, F219, F220, F241 and 
F304 form a hydrophobic roof of the CYP3A4 active site above the heme between SRS1, 
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SRS2, SRS3 and SRS4 117,118.  Another phenylalanine residue, F57, falls into a region 
recently denoted as SRS 1’a 119 and is important for CYP3A4 substrate binding 120. In 
contrast, information regarding the importance of particular CYP3A5 active site residues 
is very limited. Due to the high similarity between CYP3A4 and CYP3A5, the overall 
folding of CYP3A5 has been predicted to be largely similar to that of CYP3A4 9. 
Mutation of divergent SRS residues of CYP3A4 to the corresponding amino acids of 
CYP3A5, P107S, F108L, N206S, L210F, V376T, S478D, and L479T, resulted in a shift 
of the aflatoxin B1 metabolite profile of CYP3A4 towards that of CYP3A5 110. However, 
the effects of the reverse mutations on CYP3A5 activity remain unknown.  
Maraviroc is an anti-HIV drug that acts by blocking the virus co-receptor, chemokine 
receptor CCR5 at the viral entry step thereby preventing viral infection 121,122. In addition, 
there is increased interest in the development of maraviroc as an oral and/or topical 
microbicide for use in HIV prevention. Maraviroc undergoes extensive metabolism in 
human body after oral administration. N-dealkylation and oxidation are the two major 
metabolizing pathways 123. CYP3A4 was reported to be the primary enzyme for N-
dealkylation whereas enzymes responsible for oxidation remain unknown (Figure 4-1). 
Monooxidation results in oxygen insertions on difluorocyclohexane ring, phenyl ring and 
triazol moiety of the maraviroc molecule. Dioxidative products have been found and 
proposed to have one oxygen insertion on difluorocyclohexane ring and the other one on 




Figure 4-1. Previously proposed pathways of maraviroc metabolism. N-dealkylation 
and oxidation are the two major pathways. Mono-oxidative products have oxygen 
insertions on three possible positions. Di-oxidative products have been proposed to have 
one oxygen insertion on difluorocyclohexane ring and the other one on triazole moiety. 
CYP3A4 is the primary enzyme for N-dealkylation. Question mark (?) represents 









In the present study, we performed a comprehensive analysis on the enzymes involved in 
maraviroc oxidative metabolism. Our enzyme kinetic studies revealed that CYP3A5 has a 
higher capacity to metabolize maraviroc to a major monooxygenated metabolite than 
CYP3A4. Plasma and urine isolated from a human subject genotyped as wild type for 
CYP3A5 confirmed that this metabolite is, indeed, the most abundant maraviroc product 
formed in vivo, as well. Further, we then leveraged this observation and systematically 
mutated CYP3A5 towards CYP3A4 using formation of this metabolite as an activity 
probe to identify residues in CYP3A5 that confer specificity with regard to maraviroc 
metabolism. In addition, we identified four novel dioxygenated maraviroc metabolites 
and two glucuronidated metabolites and confirmed their existence in human urine 
samples. Collectively, these studies provide novel mechanistic insight into the phase I 
and phase II metabolism of maraviroc as well as the role of divergent amino acids of 














Materials and Methods 
Materials  
Maraviroc was obtained from the National Institutes of Health AIDS Research and 
Reference Reagent Program (Germantown, MD). Maraviroc-d6, 3-hydroxymethyl 
maraviroc, and 4-hydroxyphenyl maraviroc were obtained from Toronto Research 
Chemicals Inc (North York, Ontario, Canada). Chemical structures of maraviroc, 3-
hydroxymethyl maraviroc, and 4-hydroxyphenyl maraviroc are shown in Figure 4-2. 
Quinidine, ketoconazole, sulfaphenazole, (+)-N-3-benzylnirvanol and furafylline were 
purchased from Sigma-Aldrich (St. Louis, MO). 2-phenyl-2-(1-piperidinyl) propane was 
bought from Santa Cruz Biotechnology (Santa Cruz, CA). Pooled human liver 
microsomes (20 mg/ml, pool of 200, mixed gender) and one lot of CYP3A5*3/*3 human 
liver microsomes were purchased from XenoTech, LLC (Lenexa, KS). The NADPH 
regenerating system, BD Biosciences UGT Reaction Mix (consisting of two reagents: 
solution A (25 mM UDPGA) and solution B (5×-UGT Assay Buffer containing 
alamethicin)), CYP3A4 and CYP3A5 primary antibodies, CYP3A5*1/*1 and 
CYP3A5*3/*3 human liver microsomes, SupersomesTM containing cDNA-expressed 
human CYP1A2, CYP2B6, CYP2C8, CYP2C9*1, CYP2C19, CYP2D6*1, CYP3A4, and 
CYP3A5, co-expressed with reductase, were purchased from BD Biosciences (San Jose, 
CA). The β-actin antibody and cell lysis buffer were obtained from Cell Signaling 
Technology (Danvers, MA). The bicinchoninic acid assay kit and SuperSignal West Dura 




Figure 4-2. Structures and molecular weights of chemicals. Structures of maraviroc 
(A), internal standard maraviroc-d6 (B), and commercially available oxidative metabolite 
standards 3-hydroxymethyl maraviroc (C) and 4-hydroxyphenyl maraviroc (D) are shown 























Incubation conditions for human liver microsome metabolism experiments.  
The metabolism experiments using human liver microsomes were carried out in a volume 
of 500 µl in 10 × 75 mm borosilicate glass tubes (Fisher Scientific). One µl of 10 mM 
maraviroc in methanol was added into a 500 µl reaction system containing 0.1 M 
potassium phosphate buffer (pH 7.4), 0.5 mg/ml human liver microsomes and incubated 
for 5 min at 37°C in a water bath. The reaction was initiated by addition of the NADPH 
regenerating system and allowed to proceed for 30 min at 37°C. For the chemical 
inhibition assays, furafylline (20 µM), 2-phenyl-2-(1-piperidinyl) propane (30 µM), 
sulfaphenazole (20 µM), (+)-N-3-benzylnirvanol (10 µM), quinidine (10 µM) and 
ketoconazole (10 µM) were used to inhibit CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4/5, respectively, in order to investigate the involvement of these 
individual CYP enzymes in the formation of maraviroc oxidative metabolites. The 
inhibitors were pre-incubated with the human liver microsomes and NADPH 
regenerating system for 10 min prior to the addition of 1 µl of 10 mM maraviroc to 
initiate the reactions. For reactions containing CYP3A5 genotyped human liver 
microsomes, a final concentration of 2 µM maraviroc was used in a total reaction volume 
of 250 µl with other components being kept at the same concentrations as described 
above. For glucuronidation reactions, UGT reaction solutions containing 25 mM UDPGA 
and 5×-UGT assay buffer with alamethicin were added into the above pooled human liver 
microsome reaction systems following addition of the NADPH regenerating system.  
Incubation conditions for individual cDNA-expressed P450s  
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One pmole of human recombinant P450 enzyme (CYP1A2, CYP2B6, CYP2C8, 
CYP2C9*1, CYP2C19, CYP2D6*1, CYP3A4, or CYP3A5) was pre-incubated with 20 
µM maraviroc in 0.1 M potassium phosphate buffer (pH 7.4) at 37°C for 5 min and the 
reaction was initiated by addition of the NADPH regenerating system (final reaction 
volume of 100 µl) and continued for 30 min at 37 °C.  
Enzyme kinetics for CYP3A4 and CYP3A5  
Maraviroc stock solution (600 mM) was prepared in DMSO and diluted into working 
solutions (0.02, 0.2, 2, 6, 20, 60, 200 mM). The working solution (0.5 µl of each) was 
then pre-incubated with 13 pmole CYP3A4 or CYP3A5 at 37°C for 5 min in 0.1 M 
potassium phosphate buffer (pH 7.4). The final concentrations of maraviroc were 0.1, 1, 
10, 30, 100, 300, and 1000 µM in a total reaction volume of 100 µl. The reaction was 
initiated by addition of NADPH regenerating system and allowed to proceed for 30 min 
at 37 °C.  
The enzyme concentrations as well as the incubation time were chosen based on 
preliminary results demonstrating that the formation of oxidative metabolites was linear 
under these conditions.  The metabolite concentrations were estimated against a standard 
curve with a range of 0.024-200 pmol maraviroc. 
Sample preparation after incubation  
At the end of the incubation, 2 reaction volumes of acetonitrile were added to stop the 
reaction. The internal standard maraviroc-d6 (100 µl of 20 ng/ml), an analogue of 
maraviroc labeled with six deuteriums, was added and the samples were vortexed. The 
mixture was then centrifuged at 3000 ×g for 10 min at 4 °C and the supernatants were 
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dried under a stream of nitrogen gas at 50 °C. The samples were reconstituted in 50 µl 
methanol and transferred to vials containing 40 µl of 5% acetonitrile/95% water/0.1% 
formic acid for injection onto the Ultra Performance Liquid Chromatography-Mass 
Spectrometry (UPLC-MS) system.  
Analysis of maraviroc and metabolites using UPLC-MS  
Maraviroc and its metabolites were detected by UPLC-MS using a Waters ACQUITY 
UPLC interfaced to an AB SCIEX QTRAP 5500 mass spectrometer. Aliquots of 
reconstituted samples were injected onto a 1.7 µm Waters UPLC BEH 2.1 x 100 mm C8 
column. Analyte resolution was achieved at a flow rate of 0.35 ml/min with 
chromatography at room temperature. Mobile phases were 5% acetonitrile – 0.1% formic 
acid in water (A) and 5% water – 0.1% formic acid in acetonitrile (B), programmed at 0% 
B from 0 to 1.1 min, 20% B from 32 to 33 min, and 0% B from 33.1 to 34 min. Detection 
of the analytes and the internal standard was achieved via multiple reaction monitoring 
for quantification under positive mode. The monooxygenated maraviroc metabolites were 
monitored using m/z of precursor/product ion pairs at 530/296 and 530/280. The di-
oxidative metabolites were monitored at m/z 546/421 and the glucuronidated metabolites 
were monitored at m/z 706/581 and 706/389. Maraviroc and the internal standard 
maraviroc-d6 were monitored at m/z of 514/389 and 520/389, respectively. The N-
dealkylated metabolite of maraviroc was monitored at m/z of precursor/product ion pairs 
at 235/110. For maraviroc metabolite identification, MS3 scans were performed with 
1st/2nd precursor ions of maraviroc, monooxygenated, dioxygenated, and glucuronidated 
metabolites at m/z 514/280, 530/296 and 546/312, respectively. For glucuronides, MS3 
scans were performed with 1st/2nd precursor ions at m/z 706/581 and at m/z 706/389. All 
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the data were acquired under positive mode and analyzed by AB SCIEX Analyst 
software (Version 1.5.1) in Windows XP Professional Version 2002. 
Maraviroc metabolite analysis in human plasma and urine  
A healthy male subject was recruited for maraviroc oxidative metabolite analysis after 
providing written informed consent for participation in a protocol approved by the 
institutional review board of Johns Hopkins Medical Institutions.  The subject was 
genotyped for CYP3A5 using a previously reported method 15. A single dose of 300 mg 
maraviroc was administrated orally followed by blood and urine collection over a 24 h 
period. Blood (10 mL) samples were collected into a heparinized tube pre-dose and 1, 2, 
4, 6, 8, and 24 h following the administration. Urine samples were collected with 
intervals of 0-2, 2-4, 4-6, 6-8, and 8-24 h after drug administration. Plasma was prepared 
by centrifugation of blood at 1,000 ×g for 10 min at 4 °C. For metabolite analysis, 100 µl 
of plasma was mixed with 300 µl methanol. Following centrifugation, the supernatant 
was dried and reconstituted for analysis as described above by UPLC-MS. For urine 
samples, 100 µl of sample was directly dried and reconstituted using methanol for 
metabolite analysis. 
Site-directed mutagenesis and expression of CYP3A4 and CYP3A5  
Plasmids pCMV6-XL4 containing CYP3A4 and CYP3A5 full length cDNAs 
(TrueClones®) were obtained from OriGene Technologies. Mutations were made with 
primers (Table 4-1) using a QuikChange lightning site-directed mutagenesis kit 
following the manufacturer's instructions. Plasmid DNA was isolated using GeneJETTM 
plasmid miniprep kit (Thermo Scientific) and DNA sequencing was performed to 
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confirm the presence of a desired mutation and the absence of extraneous mutations. The 
plasmid constructs (4 µg) were transfected into COS-7 cells using lipofectamine 2000 

















Table 4-1. Sequence of oligonucleotides used for site-directed mutagenesis for 
CYP3A4 and CYP3A5a. 





































































a The underlined nucleotide(s) in bold represent the introduced mutations that were used to make the 
desired residue changes. b Three nucleotides were omitted in the primer sequence in order to delete residue 










Analysis of metabolite formation by CYP3A4 and CYP3A5 expressed in COS-7 cells  
Twenty-four hours following transfection, maraviroc was added to a final concentration 
of 20 µM in 1 ml of DMEM per well. After 40 min incubation, 600 µl or 300 µl medium 
were transferred to glass tubes and mixed with 50 µl of 20 ng/ml maraviroc-d6 for cells 
expressing CYP3A4 and CYP3A5, respectively. Two volumes of acetonitrile were 
added, vortexed, and centrifuged at 3000 ×g for 10 min at 4 °C. Supernatants were 
transferred, dried, reconstituted and analyzed following the procedure described above. 
Immunoblot analysis of CYP3A4 and CYP3A5 expression  
Cells were harvested in 1 ml PBS followed by centrifugation at 500 ×g for 5 min at 4 °C. 
The cell pellets were then resuspended in cell lysis buffer containing freshly added 
phosphatase and protease inhibitor cocktail (Thermo Scientific Halt Protein and 
Phosphatase Inhibitor Cocktail) and phenylmethylsulfonyl fluoride (PMSF). The 
resuspended cell pellets were passed 30 times through a 25G gauge needle for lysis and 
centrifuged at 14,000 ×g for 10 min at 4 °C. Protein concentrations were measured using 
a bicinchoninic acid assay kit (Thermo Scientific) and 20 µg total protein was loaded 
onto a 10% polyacrylamide gels for separation by SDS-PAGE. Immunoblotting was 
performed using anti-CYP3A4, anti-CYP3A5 antibodies and β-actin for normalization. A 
Carestream 4000R system was used for chemiluminescent imaging followed by 
densitometrical analysis.  
Statistical analysis  
Km and Vmax values were determined by nonlinear regression analysis using GraphPad 
Prism 5 for Windows (GraphPad Software Inc., San Diego, CA). All data presented are 
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means ± SD from three independent experiments performed in duplicate. Two-tailed 


























Detection of monooxygenated metabolites of maraviroc using UPLC-MS  
Using a novel UPLC-MS method that was specifically developed for the detection and 
separation of maraviroc and its oxidative metabolites, six major monooxidative 
metabolites were identified from incubations with human liver microsomes. Herein, these 
metabolites are denoted as metabolite 1- metabolite 6 (M1-M6; numbered by order of 
elution) with retention times of 14.9, 16.2, 16.9, 21.7, 22.6 and 27.0 min, respectively 
(Figure 4-3A, B). The retention time for maraviroc was 25.08 min (Figure 4-3C). 
Among the six metabolites, M1, M2, and M3 were the predominant metabolites. To 
confirm the formation of these monooxygenated products of maraviroc in vivo, a single 
300 mg dose of maraviroc was administered orally to a healthy volunteer followed by 
blood and urine collection and metabolite analysis using UPLC-MS. Genotyping results 
of CYP3A5 determined this subject to be homozygous for wild type CYP3A5 allele *1. 
We found that these six metabolites were the major products present in both plasma 
(Figure 4-4A) and urine (Figure 4-4B). A secondary amine product resulting from N-
dealkylation of maraviroc has been previously found in plasma and excreta 123,124. 
Therefore, in order to gain a more comprehensive view of maraviroc biotransformation, 
we also monitored the formation of this metabolite using our assay. We found that the 
peak area ratio of formation of this N-dealkylated metabolite to M1 by human liver 
microsomes was 0.3. In addition, consistent with previous findings, we also detected the 
N-dealkylated metabolite of maraviroc in both human plasma and urine samples. The 
peak area ratio of the N-dealkylated maraviroc to M1 ranged from 0.3-2.6 and 1.4-6.4 in 
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plasma and urine samples, respectively, over a period of 24 h following a single oral dose 
of maraviroc administration.  
CYP3A5 has a higher capacity to form M1 than CYP3A4 
To determine which CYP isozymes play a role in the formation of these metabolites, 
maraviroc was incubated with a panel of cDNA-expressed P450s. As shown in Figure 4-
5 CYP3A4 and CYP3A5 were essentially the only enzymes that catalyzed the formation 
of monoxygenated products of maraviroc. Among the six metabolites, M1 was the most 
abundant and formation by CYP3A5 was 9.7-fold greater than by CYP3A4. To further 
confirm the role of CYP3A4 and CYP3A5 in M1 formation, maraviroc was incubated 
with human liver microsomes in the presence of inhibitors of CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 (Figure 4-6). Ketoconazole, an inhibitor 
of CYP3A4/5, significantly reduced the activity by 81% (P < 0.001). Quinidine, a 
CYP2D6 inhibitor, decreased formation of M1 16%, however, this was not statistically 
significant when compared to the vehicle control (P = 0.12). The Vmax values for M1 
formation by CYP3A4 and CYP3A5 were 0.04 ± 0.001 pmole/min/pmole P450 and 0.93 
± 0.04 pmole/min/pmole P450, respectively, and the Km values were 11.1 ± 2.1 µM and 
48.9 ± 7.6 µM, respectively (Figure 4-7). At 1 µM maraviroc, which is within the 
clinically useful range of maraviroc concentrations, formation by CYP3A5 was 9-fold 
higher than that of CYP3A4 (Figure4-7 inset), indicating that CYP3A5 may play a 





Figure 4-3. Separation of maraviroc oxidativemetabolites using a novel 
chromatographic method. Chromatograms of oxidative metabolites M1-M5 (A), 
oxidative metabolite M6 (B) and maraviroc (C). Retention times (min) are shown near 
corresponding peaks. Human liver microsmes were incubated with 20 µM maraviroc for 
30 min at 37°C and reactions were terminated by acetonitrile. The analytes were 
separated using a Waters Acquity UPLC BEH C8 1.7mm 2.1×100 mm column and 
analyzed by mass spectrometry under MRM mode with transitions m/z 530→296 for 
















Figure 4-4. Separation of oxidative metabolites from human plasma samples after 
an oral dose of maraviroc. The human plasma (A) and urine (B) chromatogram are 
representative data obtained 2 h and 2-4 h, respectively, following a single oral dose of 
300 mg maraviroc. Metabolites were analyzed by mass spectrometry using the transitions 

















Figure 4-5. CYP3A4 and CYP3A5 are the major enzymes responsible for maraviroc 
oxidation. A panel of cDNA-expressed P450s was incubated with maraviroc followed by 


















Figure 4-6.  Ketoconazole inhibited M1 formation. CYP chemical inhibitors were 
preincubated with human liver microsomes prior to the addition of maraviroc. The data 
are presented as percent M1 formation activity remaining relative to vehicle control. The 
CYP enzyme targeted by the particular chemical inhibitor is shown at the top of the 
figure. PPP is the abbreviation for 2-phenyl-2-(1-piperidinyl) propane. ***P < 0.001 
















Figure 4-7.  M1 formation rate by CYP3A5 is greater than that by CYP3A. cDNA-
expressed CYP3A4 and CYP3A5 were incubated with 0.1-1000 µM maraviroc under 
initial rate conditions. M1 formation was determined using a maraviroc standard curve 
and maraviroc-d6 as an internal standard. Kinetics data at maraviroc concentrations in the 
















Reduced M1 formation by human liver microsomes genotyped as homozygous for 
the loss-of-function CYP3A5*3 allele 
The expression and activity of CYP3A5 has been reported to be affected by genetic 
polymorphisms. Individuals who carry two CYP3A5*3 alleles (CYP3A5*3/*3) have 
reduced or no expression of CYP3A5 compared to those homozygous for the wild type 
CYP3A5*1 allele 15,16. We measured M1 formation by human liver microsomes isolated 
from individuals genotyped as CYP3A5*1/*1 and individuals genotyped as 
CYP3A5*3/*3 in order to determine the contribution of CYP3A5 to M1 formation in a 
system where CYP3A4 is present while CYP3A5 expression is absent or markedly 
reduced. In addition, these studies were used to probe the utility of M1 formation as a 
CYP3A5 phenotyping tool. Following incubation with maraviroc (2 µM) the human liver 
microsomes isolated from donors homozygous for the CYP3A5*3 alleles, exhibited a 
79% decrease in formation of M1 as compared to production by human liver microsomes 
isolated from donors homozygous for the CYP3A5*1 allele (Figure 4-8A, p = 0.01). 
Furthermore, M1 was the most abundant metabolite formed using the CYP3A5*1/*1 
human liver microsomes (Figure 4-8B). In human liver microsomes genotyped as 







Figure 4-8. Decreased M1 formation in human liver microsomes genotyped as 
CYP3A5*3/*3. (A) Reduced M1 formation by human liver microsomes homozygous for 
a CYP3A5 nonfunctional allele. Human liver microsomes from individuals genotyped as 
CYP3A5*1/*1 or CYP3A5*3/*3 were incubated with 2 µM maraviroc and M1 formation 
was measured. Each data point represents the peak area ratio of M1 to maraviroc-d6 
(internal standard). The mean for each group is indicated by a horizontal line. (B) and (C) 
are representative chromatogram of oxidative metabolites from reactions of 
















M1 is formed via hydroxylation of the difluorocyclohexane ring of maraviroc 
To determine the position of the CYP-dependent monooxygenation that results in the 
formation of M1, mass spectrometry was performed using MS2 and MS3 scans following 
the UPLC separation of M1 from other maraviroc oxidative metabolites. These spectra 
were then compared to maraviroc as well as commercially available synthetic standards 
for 3-hydroxymethyl maraviroc, a metabolite with a hydroxyl group on the triazole 
moiety, and 4-hydroxyphenyl maraviroc, a metabolite with a hydroxyl group on the 
phenyl ring. Fragmentation of maraviroc resulted in two major daughter ions with m/z of 
389 and 280, respectively, from losing the triazol moiety and the breakage at the tertiary 
amine nitrogen of the tropane ring (Figure 4-9A) 125. The spectrum of 3-hydroxymethyl 
maraviroc was similar to that of maraviroc because the oxygen is on the triazol moiety, 
which was not included in the two major daughter ions after fragmentation. The 
fragmentation of M6 was similar to that of 3-hydroxymethyl maraviroc, indicating the 
oxygen insertion was on the triazol moiety. In contrast, fragmentation of 4-
hydroxyphenyl maraviroc had two major daughter ions with m/z of 405 and 296, 
respectively, with 16 D increase due to an oxygen insertion on the two major daughter 
ions with m/z of 389 and 280. Similar to 4-hydroxyphenyl maraviroc, MS2 scans of M1-
M5 resulted in two major product ions at m/z 296 and 405 (Figure 4-9B), which contains 
the difluorocyclohexane ring and phenyl ring of maraviroc but not the triazole moiety. 
Thus, we propose that the m/z 296 ion of M1 represents an oxygen (16 Da) insertion into 
this portion of the molecule suggesting that the site of metabolism is either on 




Figure 4-9. MS/MS spectra of maraviroc and its hydroxylated metabolites. (A) 

























To test this further, selected daughter ions were fragmented for analysis using MS3 scan. 
Maraviroc daughter ion m/z 280 produced product ions at m/z 91, 106 and 117 (Figure 
4-10A). The ions with m/z 106 and 117 have been identified as phenyl ring containing 
product ions of maraviroc 125,126. In contrast, fragmentation of 4-hydroxyphenyl 
maraviroc daughter ion m/z 296 generated ions at m/z 122 and 133 (Figure 4-10B), 
products resulting from one oxygen insertion on the phenyl ring containing ions m/z 106 
and 117, respectively. Unlike 4-hydroxyphenyl maraviroc but similar to maraviroc, 
fragmentation of M1 yielded phenyl ring containing product ions at m/z 106 and 117 
(Figure 4-10C). From these data, it was concluded that M1 formation did not involve 
oxygenation of the phenyl ring. Taken together, since M1 formation did not appear 
involved oxygen insertion on either the triazole ring or the phenyl ring of maraviroc, the 
oxygen insertion was assigned on the difluorocyclohexane ring (Figure 4-10D), which 
matched other product ions (Figure 4-10C). Fragmented ions with a loss of HF (20 Da) 
and CH2=CH2 (28 Da) from m/z 296 were found at 276 and 268, respectively. The loss of 
both HF and water (18 Da) from m/z 296 generated ions at m/z 258. A further loss of 
CH2=CH2 (28 Da) produced ions at m/z 230 (Figure 4-10C). MS2 and MS3 scans were 
also used to confirm that M2-M6 were indeed monooxygenated products as well and 








Figure 4-10. M1 results from oxygen insertion on the difluorocyclohexane ring of 
maraviroc as determined by mass spectrometry. MS3 spectra of (A) maraviroc, (B) 4-
hydroxyphenyl maraviroc and (C) M1. (D) The proposed structure of M1. MS3 scans 
were performed using 1st/2nd precursor ions at m/z 514/280 for maraviroc and at m/z 






















Mutation of residues that are divergent between CYP3A4 and CYP3A5 alters M1 
formation 
Since studies have yet to be performed to identify the CYP3A5 residues that might confer 
substrate specificity, we leveraged our finding that M1 is formed preferentially by 
CYP3A5 over CYP3A4 and mutated several CYP3A5 residues predicted to be within 
SRSs based on alignment with CYP3A4. A number of residues outside of the predicted 
CYP3A5 SRSs were mutated to the corresponding amino acids of CYP3A4 as well in 
order to evaluate their contribution to the differential metabolism of maraviroc by these 
















Figure 4-11. Mutations of divergent residues between CYP3A4 and CYP3A5. The 
mismatched residues evaluated in this study are underlined and in bold font. The six 














COS-7 cells were used as a model system for expression of CYP3A4 and CYP3A5 since 
they have been proven to express endogenous NADPH-cytochrome P450 reductase 
which is necessary to support CYP enzyme-mediated metabolism 128. The untransfected 
cells did not exhibit activity towards maraviroc (data not shown).  After transfection, 
protein expression of wild type CYP3A5 and all mutants was measured using 
immunoblotting (Figure 4-12). Similar to the maraviroc metabolism studies carried out 
using human liver microsomes, the CYP3A transfected COS-7 cells formed the oxidative 
metabolites of maraviroc with M1-M3 being the most predominant. Following protein 
normalization, a significant reduction in M1 formation by the L57F, S107P, L108F, 
G214D, L219F, L240V, I371M, S392V, T478L, and Q479G mutants was observed 
(Figure 4-13, p < 0.02). Among them, G214D exhibited the greatest reduction of 88% 
compared to the wild type CYP3A5. M1 formation by the L57F, L108F and S107P 
mutants of CYP3A5 was decreased by 61%, 59% and 72%, respectively. I224T mutation 
resulted in a loss of CYP3A5 expression and thus no M1 was detected. We also found 
that mutations F146V, G186S, S206N, A296V and V369I significantly increased M1 
formation (p < 0.05). Mutations of F210L, S239C and K243R did not significantly 
change the M1 formation activity of CYP3A5 (p = 0.16, 0.16, and 0.20, respectively). No 
obvious changes were detected for other mutations including F120L, K166T, K212R, 






Figure 4-12. Protein expression of CYP3A5 wild type and mutants. Plasmids 
containing wild type or mutant cDNA were transfected into COS-7 cells and maraviroc 
was added to the medium 24 h post-transfection. Protein expression was detected by 






















Figure 4-13. Changes in M1 formation resulting from mutation of CYP3A5 towards 
CYP3A4 after normalization by protein expression. At 24 h post-transfection, 
maraviroc was incubated with the cells for 40 min and metabolites were measured in the 
medium followed by protein expression measurement for normalization. SRS regions that 
the residues belong are denoted on the graph. P ≤ 0.05 for all mutants, except for F210L 
(p = 0.16), S239C (p = 0.16), and K243R (p = 0.20), when compared to wild type 


















To gain a more comprehensive understanding of the effects of the mutations of CYP3A5 
on catalytic activity we also measured the formation of M2 and M3 in addition to M1. 
Wild type CYP3A5 formed M1 at a higher level than M2 and M3 with metabolic ratios 
of M1/M2 and M1/M3 of 24.4 and 30.4, respectively (Table 1).  In contrast, M1 formed 
by CYP3A4 was comparable to formation of M2 and M3 with M1/M2 and M1/M3 ratios 
of 1.5 and 1.6, respectively.  Among the CYP3A5 mutants that were tested, L108F, 
G214D, and L57F resulted in a decrease in M1/M2 ratio by 95%, 75%, and 52%, 
respectively, as compared to wild type CY3A5. Furthermore, L108F, G214D, S107P, 
L57F, L240V and I371M decreased M1/M3 ratio by 95%, 85%, 64%, 55%, 51%, and 
51%, respectively. Thus, these mutations of CYP3A5 shifted formation of these 
metabolites towards that of CYP3A4. In addition, F146V and L219F decreased the 
metabolic ratios of both M1/M2 and M1/M3; however, the differences from wild type 
CYP3A5 were less than 50%. Unlike the other mutants, S206N increased M1/M2 and 









Table 4-2. Comparison of metabolic ratios of CYP3A5 and its mutants to that of 
CYP3A4.The indicated enzymes were transiently expressed in COS-7 cells. Metabolism 
experiments for maraviroc were carried out and oxidative metabolites M1, M2, and M3 
were measured as described under Materials and Methods. Metabolic ratios (M1/M2 and 
M1/M3) are presented as means ± SD. 
Name M1/M2 M1/M3 
CYP3A5 24.4 ± 1.3 30.4 ± 4.2 
L57F 11.8 ± 1.2 13.6 ± 1.4 
S107P 24.1 ± 2.7 10.9 ± 4.0 
L108F 1.29 ± 0.05 1.7 ± 0.03 
F146V 20.0 ± 2.9 25.6 ± 4.0 
G186S 25.4 ± 1.5 38.9 ± 3.2 
S206N 34.0 ± 2.1 47.6 ± 3.6 
G214D 6.14 ± 0.2 4.6 ± 0.03 
L219F 17.9 ± 0.4 16.7 ± 0.1 
S239C 27.3 ± 4.0 42.3 ± 3.9 
L240V 13.3 ± 6.3 14.9 ± 4.9 
V369I 18.2 ± 4.5 25.1 ± 2.8 
I371M 20.3 ± 2.8 15.0 ± 1.5 
S392V 22.5 ± 0.1 18.8 ± 2.3 
T478L 25.6 ± 2.7 38.1 ± 2.7 
Q479G 25.6 ± 2.2 23.4 ± 1.1 











Following the observation that mutation of certain CYP3A5 residues resulted in 
metabolite profile similar to that of CYP3A4 we tested whether the reverse could occur if 
residues in CYP3A4 were mutated to the corresponding mismatched residues in 
CYP3A5. We analyzed CYP3A4 mutants including F57L, P107S, F108L, D214G, 
L479T, and deletion of N423 (∆N423). CYP3A4 contains 503 amino acids while 
CYP3A5 has 502 residues. N423 is the CYP3A4 amino acid that appears to be the 
additional amino acid that is not present in CYP3A5 when the two sequences are aligned. 
Very interestingly, we found that while the L57F mutation of CYP3A5 shifted M1 
formation towards CYP3A4 with a decrease of 61% the reverse mutant of CYP3A4, 
F57L, had the opposite effect in that it increased M1 formation to 337% of that produced 
by wild type CYP3A4 (Figure 4-14). Other mutations including P107S, F108L, D214G, 













Figure 4-14. Residue 57 contributes to the differential formation of M1 by CYP3A4 
and CYP3A5. Decreased M1 formation by the CYP3A5 L57F mutant (p = 0.0002) and 
increased M1 formation by the CYP3A4 F57L mutant (p = 0.002) relative to that by wild 
type CYP3A5 and CYP3A4, respectively. Protein expression of wild type (WT) CYP3A4 
and the F57L mutant is shown above the right panel and expression of CYP3A5 L57F is 
shown in Figure 6a. Metabolite formation was normalized to protein expression as 



















Identification of novel dioxygenated maraviroc metabolites 
Using the chromatographic method for maraviroc metabolite analysis that we developed, 
four previously unreported maraviroc dioxygenated metabolites (M7-M10) were 
identified in human liver microsome reactions by monitoring the transition m/z 546/312 
(Figure 4-15A). MS2 fragmentation of the four metabolites all produced two major 
daughter ions at m/z 312 and 421, which have a 32 Da increase compared to the daughter 
ions of maraviroc m/z 280 and 389, respectively (Figure 4-15B). This suggested that the 
oxygen insertions were not on the triazole ring as neither of the fragment ions m/z 280 or 
m/z 389 contain the triazole ring. Further fragmentation of m/z 312 from M7-M10 
generated product ions m/z 106 and 117 (Figure 4-15C), the two phenyl ring containing 
ions found in the MS3 spectra of maraviroc daughter ion m/z 280 (Figure 4-10A), 
indicating that no oxygen insertions occurred on the phenyl ring of maraviroc. Therefore, 
the two hydroxyl groups were assigned to the difluorocyclohexane ring. The assignment 
was in agreement with other observed ions in the spectra namely m/z 294 and 274 that 
are products of the m/z 312 daughter ion that are formed after the loss of a water 
molecule (18 Da) and a further loss of HF (20 Da), respectively (Figure 4-15C). 
Consistent with the in vitro metabolism results using human liver microsomes, we found 
that the four dioxygenated metabolites were present in all the urine samples collected 
from the healthy volunteer (Figure 4-15D). Similar to what was observed for 
the monooxygenated metabolites, CYP3A5 and CYP3A4 catalyzed the formation of all 




Figure 4-15. Chromatograms and MSn spectra of dioxygenated metabolites. (A) 
Chromatogram of dioxygenated maraviroc metabolites (M7-M10) detected using the 
transition m/z 546→312 from metabolism reactions using human liver microsomes. (B) 
Representative MS2 spectra of M7-M10 with the precursor ion m/z 546. (C) 
Representative MS3 spectra of M7-M10 with 1st/2nd precursor ions at m/z 546/312. The 
proposed structures of fragmented ions are shown near the corresponding peaks. (D) 
Chromatogram of dioxygenated maraviroc metabolites (M7-M10) detected in urine 
















Glucuronidation of Maraviroc 
Glucuronidation has been proposed as a metabolic pathway for maraviroc in mice but not 
in humans 129; however, in the present study we have identified two maraviroc 
glucuronides that were detected using the transitions m/z 706/581 (M11, Figure 4-16A) 
and m/z 706/389 (M12, Figure 4-16A). MS3 spectra of M11 with 1st/2nd 
precursor/product ions of 706/581 contained ions at m/z 472, 296, and 133 (Figure 4-
16B).  The ion with m/z 472 is a product resulting from a glucuronic acid (176 Da) 
conjugation on the ion with m/z 296, an ion with one oxygen insertion compared to 
maraviroc daughter ion m/z 280. The ion with m/z 133 has the same mass as a product 
ion (m/z 133) of 4-hydroxyphenyl-maraviroc (Figure 4-10B). Therefore, the conjugation 
of glucuronic acid was assigned to the phenyl ring. Unlike M11, fragmentation of M12 
generated two major ions m/z 389 and m/z 280, the same two daughter ions produced via 
fragmentation of maraviroc (Figure 4-16C). MS3 spectra confirmed that these two ions 
were indeed the same in both maraviroc and M12 suggesting that the glucuronidation 
occurred on the triazole moiety following oxidation. Consistently, we also found that the 










Figure 4-16. Chromatograms and MSn spectra of maraviroc glucuronides. (A) MRM 
chromatogram of maraviroc glucuronides with transitions at m/z 706→581 (M11) and at 
m/z 706→389 (M12) from metabolism reactions using human liver microsomes. (B) MS3 
spectra of M11 monitoring 1st/2nd precursor ions at m/z 706/581. (C) MS2 spectra of M12 
monitoring precursor ion at m/z 706. The proposed structures of fragmented ions are 
shown near the corresponding peaks. (D) MRM chromatogram of maraviroc 
glucuronides with transition at m/z 706→581 (M11) and at m/z 706→389 (M12) in urine 






















In this study, a novel chromatographic method was developed for the separation and 
quantitation of oxidative metabolites and glucuronides of maraviroc. We found six major 
monooxygenated metabolites (M1-M6), four novel dioxygenated metabolites (M7-M10), 
and two previously unidentified glucuronides (M11-M12) using human liver microsomes 
and confirmed that the metabolite profile was similar in plasma and/or urine samples 
after administration of maraviroc to a healthy volunteer. The separation method that we 
developed has utility in future studies of maraviroc metabolism in both basic and clinical 
research. Further, since maraviroc is currently used clinically to treat HIV and is being 
investigated for additional use in HIV prevention, the data presented here are valuable in 
that we provide the first detailed information regarding the biotransformation of 
maraviroc both in vitro and in vivo.   
We identified CYP3A4 and CYP3A5 as the major P450s involved in maraviroc 
oxidation, which will be helpful in understanding drug-drug interactions of maraviroc 
with other drugs. It is known that maraviroc plasma concentration and exposure are 
significantly changed when co-administered with CYP3A inducers or inhibitors 130,131. 
The M1 formation activity of CYP3A5 exhibited an evident difference from that of 
CYP3A4. This was further confirmed by the observation that there was marked reduction 
in M1 formation by human liver microsomes genotyped as homozygous CYP3A5*3 
allele that do not express CYP3A5. In addition, N-dealkylation and oxidation have been 
reported to be the two major pathways responsible for the metabolism-dependent 
clearance of maraviroc 123 . Previous studies reported a Km of 21 µM and Vmax of 0.45 
pmole/min/pmole P450 for N-dealkylation of maraviroc using human liver microsomes 
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and a Km of 13 µM and Vmax of 3 pmole/min/pmole P450 for the formation of this same 
metabolite using cDNA expressed CYP3A4 124; here we demonstrated that CYP3A5 
plays a primary role in the formation of M1 with Km of 48.9 µM and Vmax of  0.93 
pmole/min/pmole P450. We also detected the N-dealkylated metabolite of maraviroc in 
both plasma and urine samples. The peak area ratio of the N-dealkylated metabolite to 
M1 in plasma varied from 0.3 to 2.6 with time over a period of 24 h after the dose, 
suggesting that monooxygenation of maraviroc may not be a minor pathway of maraviroc 
metabolism when compared to the N-dealkylation. This indicates that in addition to N-
dealkylation, monooxygenation should also be monitored in order to gain a more 
complete understanding of the mechanism(s) of maraviroc clearance. Taken together, our 
results indicate that M1 formation is primarily mediated by CYP3A5 and thus maraviroc 
is potentially useful as a probe substrate for CYP3A5. The use of maraviroc as a 
CYP3A5 probe substrate can be applied to in vitro drug-drug interaction studies to 
identify potential inducers or inhibitors of CYP3A5 in the process of drug development. 
In addition, several aspects of maraviroc make it an attractive candidate for potential 
consideration as a CYP3A5 clinical phenotyping probe: 1) it is an Food and Drug 
Administration (FDA)-approved oral drug; 2) maraviroc has an excellent clinical safety 
profile 132; 3) M1 was detected as one of the major oxidative metabolites in urine as early 
as 0-2 h following maraviroc administration (data not shown), possibly making maraviroc 
a non-invasive phenotyping probe through analysis of urine samples. Several studies have 
shown that CYP3A5 is involved in metabolism of drugs including vincristine 133-135, 
tacrolimus 136,137, and cyclosporine 138; however, these drugs all have demonstrated 
toxicities 139-142, making them less desirable as probe drugs for use in healthy volunteers. 
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We found a single residue, 57, that when mutated in CYP3A5 (L to F) shifted the 
CYP3A5-dependent M1 formation to mirror that of CYP3A4 and vice versa (CYP3A4 F 
to L). This is the first time that a residue that confers a switch in the activity between 
CYP3A4 and CYP3A5 has been identified. Our study provided the first experimental 
evidence, to the best of our knowledge, for the importance of this residue for CYP3A 
activity as well as its role in differentiating activities between CYP3A4 and CYP3A5. A 
recent crystal structure has shown that the CYP3A4 residue F57 is involved in the 
binding of the CYP3A4 substrate ritonavir 120. 
Several studies have suggested an important role for SRS1 residue F108, which resides in 
the Phe-cluster (F108, F213, F215, F219, F220, F241, and F304) that forms a 
hydrophobic roof for the CYP3A4 active site, in CYP3A4 catalytic activity117,118. 
Replacement of F108 in CYP3A4 to the corresponding CYP3A5 residue L decreased 
metabolism of testosterone and aflatoxin B1 110. The CYP3A4-ritonavir crystal structure 
showed that F108 formed a hydrophobic pocket for ritonavir binding along with several 
other residues 120. In addition, computational modeling predicted that F108 in CYP3A4 is 
involved in maraviroc binding via van der Waals interaction 143. A previous CYP3A5 
homology model constructed based on the CYP3A4 crystal structure showed that the 
overall folding of CYP3A5 overlaid with the folds of CYP3A4 9, suggesting that L108 
might be located in the roof of the CYP3A5 active site as it is in CYP3A4. Our current 
study showed that mutation L108F in CYP3A5 reduced M1 formation, confirming its 
importance to CYP3A5 activity. In addition, the formation of M2 and M3 was increased 
compared to wild type CYP3A5. The resultant metabolite profile resembles that of 
CYP3A4 with similar metabolic ratios.  Similar to residue F108, residue F219 in the 
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hydrophobic pocket of CYP3A4 is replaced by L in CYP3A5. After mutation of L to F at 
219 in CYP3A5, we also observed a reduction in M1 formation. The increased size in the 
side chain for the mutation L to F at 108 and 219 may strengthen the effects of the 
characteristic “Phe-cluster” thereby making the shape of CYP3A5 substrate binding 
pocket more like that of CYP3A4, resulting in the change of CYP3A5 activity towards 
that of CYP3A4.  
Mutation of CYP3A5 SRS2 residue G214 to CYP3A4 residue D214, a residue located 
between the hydrophobic residues F213 and F215, resulted in a pronounced effect with 
88% reduction of CYP3A5 activity for M1 formation. CYP3A4 SRS3 residue V240 
belongs to this hydrophobic ceiling of the active site along with the Phe-cluster and was 
shown to contribute to progesterone binding 118. The mutation of CYP3A5 L240V also 
resulted in a marked decrease in M1 formation. These data underscore the importance of 
the hydrophobic roof in the active site, which might play a role in CYP3A4 and CYP3A5 
substrate specificity.  
In summary, we found that CYP3A4 and CYP3A5 were the major enzymes responsible 
for maraviroc oxidation and that CYP3A5 was the primary enzyme responsible for the 
formation of a major monooxygenated metabolite of maraviroc; we determined that the 
divergent residue 57 within CYP3A4 and CYP3A5 contributed to their differential 
activities towards maraviroc; we also identified novel secondary deoxygenated and 
glucuronidated metabolites of maraviroc.  Collectively, besides filling the gap in 
understanding of maraviroc metabolism, these studies suggest that maraviroc may have 
utility as a probe substrate for CYP3A5. In addition, the present study has provided novel 
140 
 
biochemical information regarding the contribution of divergent residues to the activity 


















































Cytochrome P450 3A5 (CYP3A5) is a drug metabolizing enzyme similar to CYP3A4, 
but, unlike CYP3A4, CYP3A5 exhibits greater polymorphic expression resulting in large 
variations in blood concentrations of drugs that are metabolized preferentially by 
CYP3A5. A selective CYP3A5 substrate is useful to determine CYP3A5 activity. Our in 
vitro metabolism study results demonstrated that CYP3A5 plays a major role in the 
oxidative metabolism of the anti-HIV drug maraviroc. The present study evaluated the 
impact of CYP3A5 genotype on the pharmacokinetics of maraviroc. After screening 
CYP3A5 genotyping, we evaluated twenty-four research participants in 3 groups of eight 
participants each: CYP3A5 homozygous wild type (two CYP3A5*1 alleles), 
heterozygous (one CYP3A5*1 allele and one mutant allele), and mutant (no CYP3A5*1 
alleles). Participants received an oral dose of 300 mg maraviroc and blood was sampled 
over a period of 32 h. The homozygous wild type group had 41% lower maraviroc area 
under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) and 66% 
higher apparent clearance compared with the mutant group. Maraviroc AUC0-inf in the 
heterozygous group was 16% lower but this difference was not statistically significant 
when compared to the mutant group. The M1 AUC0-inf was 224% and 157% in the 
heterozygous and homozygous wild type group, respectively, relative to that in the 
mutant group. The AUC0-inf ratios of maraviroc to M1 in heterozygous and homozygous 
wild type group were lower by 51% and 64% when compared with the mutant group, 
respectively. Plasma concentration ratios and AUC0-inf ratios of maraviroc to M1 were 
well correlated at 4 h post dose administration. These results suggest that maraviroc can 




AUC, area under the plasma concentration-time curve, AUC; AUC0-inf, area under the 
curve from time to infinity; AUCmaraviroc/AUCM1, AUC0-inf ratio of maraviroc to M1; 
BMI, body mass index; Cmax, plasma peak concentration; CL/F, oral apparent clearance; 
CrCL, creatinine clearance; CYP3A5, Cytochrome P450 3A5; FDA, Food and Drug 
Administration; IQR, interquartile range; PCR, polymerase chain reactions; Tmax, time to 
reach Cmax; T1/2, half-life; UPLC, Ultra Performance Liquid Chromatography; V/F, 
volume of distribution.  
Introduction 
Cytochromes P450 (CYP)-dependent metabolism is an important pathway for drug 
elimination144. CYP-mediated biotransformation usually converts drugs to more polar 
metabolites to facilitate their excretion into bile or urine. When two or more drugs are co-
administered, if one drug is cleared through CYP-mediated metabolism and the other 
drug has an inhibitory or inductive effect on the CYP enzyme, the substrate drug blood 
concentration may be increased resulting in toxicity or decreased leading to treatment 
failure. Similarly, the variation in CYP expression also leads to changes in the blood 
concentration of their substrate drugs. Using a CYP substrate as a phenotyping probe to 
measure in vivo activity of a CYP enzyme is valuable in the process of drug development 
to identify drugs or dietary supplements that have potential modulatory effects on these 
enzymes, especially when the substrate drug has a narrow therapeutic window.  
CYP3A4 and CYP3A5, two major CYP3A subfamily enzymes, play predominant roles 
in drug metabolism by catalyzing the biotransformation of more than 50% of marketed 
drugs; however, the substrate spectra of these two enzymes largely overlap due to high 
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similarity at the amino acid level making discovery of selective substrates difficult. Over 
the years, efforts have been focused on the development of CYP3A4 phenotyping probes 
because CYP3A4 has been thought to be the major CYP3A isoform in liver; however, 
CYP3A5 has received increased attention in recent years due to the fact that it is highly 
polymorphic and thus, its expression is highly variable. The wild type CYP3A5*1 allele 
is associated with the highest expression level of CYP3A5, whereas changes in the 
mRNA splicing site due to single nucleotide polymorphisms (CYP3A5*3, CYP3A5*6) 
or in the reading frame due to a T insertion (CYP3A5*7) result in lower expression or no 
activity of CYP3A5 16,19,145,146. CYP3A5*2 had a nucleotide transition from C to A, 
causing an amino acid change from threonine to asparagine in the CYP3A5 protein so 
that the enzyme is not fully functional18. The most common nonfunctional allele 
CYP3A5*3 is abundantly present in the European American population and < 10% of 
them express CYP3A5. In contrast, CYP3A5*1 has high frequency in the African 
American population and > 60% of them express CYP3A516,18-20. In individuals who are 
expressers, CYP3A5 protein accounts for > 50% of total liver CYP3A and even several-
fold higher than that of CYP3A457,58. Several studies have shown that variations in 
CYP3A5 expression contribute to changes in the plasma concentrations of its substrate 
drugs147-151. Increased risk of drug toxicities has been reported in people with low 
CYP3A5 expression. Conversely, unexpected high expression of CYP3A5 could result in 
low blood drug concentrations leading to compromised drug efficacy and even life-
threatening treatment failures. Therefore, a clinical probe that is used to measure 
CYP3A5 in vivo activity will help to identify drugs that are CYP3A5 inhibitors or 
inducers in order to prevent toxicity or treatment failure in multi-drug using patients. 
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Our in vitro work showed that CYP3A5 is the major enzyme responsible for formation of 
the maraviroc metabolite, M1. Human liver microsomes isolated from donors 
homozygous for the nonfunctional CYP3A5*3 allele exhibited a significant decrease in 
M1 formation compared with those homozygous for the wild-type CYP3A5*1 allele, 
indicating that the biotransformation from maraviroc to M1 could be used to measure 
CYP3A5 activity. Since maraviroc is an anti-HIV drug with an excellent safety profile 
that could be given to healthy volunteers, it may have the potential to be used as a clinical 
CYP3A5 phenotyping probe. Therefore, we extended these in vitro observations to 
further investigate the clinical value of maraviroc in CYP3A5 metabolic phenotyping by 
evaluating the influence of CYP3A5 genotype on pharmacokinetics of maraviroc and 
metabolite M1.  
Materials and Methods 
Subjects and study design 
This was an open label, single dose study. Inclusion criteria included age 18–65 years, 
healthy with no acute medical illness, no evidence of hepatic or renal impairment (liver 
function tests values < 1.5 Upper Limit of Normal (ULN), total bilirubin below ULN, 
creatinine clearance > 60 mL/min), and negative HIV test results. Any concomitant 
medications or herbal supplements for which there is a known risk of pharmacokinetic or 
pharmacodynamics drug interactions, including those that inhibit CYP3A family 
enzymes, were prohibited for 4 weeks prior to and during the study. The study was 
reviewed and approved by the institutional review board of The Johns Hopkins Medical 
Institutions and was conducted in compliance with national and local institutional 
guidelines. All participants gave written informed consent. 
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Healthy volunteers were screened by CYP3A5 genotyping (*1, *2, *3, *6, and *7) for 
enrollment into 3 groups of 8 research participants (24 total sample size) based on the 
status of CYP3A5 genotype: homozygous wild type (2 CYP3A5*1 alleles), heterozygous 
(1 CYP3A5*1 allele and 1 mutant allele), and  without wild type genotype (2 mutant 
alleles). A single dose of 300 mg maraviroc tablet was given to the volunteers orally 
along with 200 mL water under direct observation. Ten mL of venous blood before (0 h) 
and 1, 2, 3, 4, 6, 8, 10, 24 and 32 h after the drug administration was drawn from each 
subject into heparinized tubes. Plasma was prepared by centrifugation of blood at 1,500 × 
g for 10 min at 4 °C and stored at -80 °C.  
Preparation of stock solutions, calibration standards and quality control samples 
An isotopically-labeled analog of maraviroc, 2H6- maraviroc, was used as an internal 
standard in quantitative analysis of maraviroc and its metabolites. All master stock 
solutions were prepared in acetonitrile at 1 mg/mL. Working solutions were serial 
dilutions of master stocks into acetonitrile. Calibration standards and quality controls 
were prepared by spiking freshly-made working solutions into EDTA K2 plasma. Since 
the true chemical standard of M1 is unavailable, 4-hydroxyphenyl maraviroc whose m/z 
ratios of precursor/daughter are similar to M1 was used to make calibrators and quality 
controls to determine the concentration of M1. The calibration range was linear from 
0.5−1,000 ng/mL for maraviroc and 0.25−1,000 ng/mL for M1. Stock solutions, 
calibration standards and quality control samples were stored at −80°C until use.  
Measurement of plasma concentrations of maraviroc and M1 
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Patient plasma samples, standards, and quality controls were thawed, vortexed, and 
processed at room temperature.  Fifty microliters of plasma was mixed with 50 µl of 
acetonitrile containing 10 ng/mL internal standard, 2H6- maraviroc.   
For maraviroc, the 100 µL mixture was transferred to a filtration plate (Agilent Captiva 
0.45 µm polypropylene, Lake Forest, CA). Then 500 µl of acetonitrile was added for 
protein precipitation.  Following a period of 5-min incubation, vacuum was applied and 
filtrates were collected into a 96-well plate.  Eluents were dried under a dry nitrogen 
stream and reconstituted in 100 µl of a 1:1 water containing 0.1% formic acid (mobile 
phase A): acetonitrile containing 0.1% formic acid (mobile phase B) mixture.  The plate 
was sealed with a polypropylene mat caps (Waters) and put into the autosampler at 4 ºC.  
Ten microliters of reconstituted sample was injected onto a reversed-phase Waters BEH 
C8 Ultra Performance Liquid Chromatography (UPLC) column (1.7 µm, 50 × 2.1 mm) at 
room temperature (20-24 ºC) and analytes were detected over 5 minute with a flow rate 
of 1 mL/min using AB SCIEX API 4000 mass spectrometer.  Mobile phases were 
programmed at 20% B from 0 to 1 min, 50% B from 1.0 to 1.5 min, 95% B from 2 to 3.5 
min, and 20% B from 3.8 to 5 min. The MRM transitions were determined by the direct 
infusion of the authentic standard and deuterated analogs into the mass spectrometer ion 
source by positive electrospray.  Detection of the analytes and internal standards was 
achieved via multiple reaction monitoring. The mass-to-charge ratios of characteristic ion 
pairs (precursor > product), individually optimized voltages, and retention times of 
analytes and internal standards are presented in Table 5-1. Signal levels of carbon-12 
maraviroc were too high to be monitored over the desired range so the carbon-13 isotope 
of maraviroc was chosen as the maraviroc transition. The multiple reaction monitoring 
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ions and transitions monitored were as follows:  maraviroc m/z 515.3 > 390.2; 2H6-
maraviroc m/z 520.6 > 389.1.  Via this method, maraviroc can be detected over an 
analytical measuring range of 0.5 − 1,000 ng/mL. Samples above the upper limit of 
quantitation were diluted, 1:3 sample:EDTA blank plasma, and re-evaluated. The method 
was developed and validated by the Clinical Pharmacology Analytical Laboratory in the 
Division of Clinical Pharmacology at The Johns Hopkins School of Medicine. Briefly, 
inter-and intra-assay precision was ≤ 5.38% and ≤ 5.98%, respectively; inter-and intra-
assay accuracy was ≤ 10.2% and ≤ 8.44%, respectively. These validation results 
exceeded standards recommended by Food and Drug Administration (FDA) and a 
manuscript has been recently accepted for publication152.  
For measurement of plasma M1, 500 µl of acetonitrile was added into the 100 µl mixture 
of plasma and internal standard followed by 5 min incubation for protein precipitation 
and transfer to a filtration plate. Then vacuum was applied and filtrates were collected 
into a 96-well plate.  Eluents were dried under a dry nitrogen stream and reconstituted in 
75 µl of mobile phases A (5% acetonitrile – 0.1% formic acid in water) and B (5% water 
– 0.1% formic acid in acetonitrile) by vortexing for 30 s. Ten microliters of reconstituted 
sample was injected onto the same UPLC column (1.7 µm, 50 × 2.1 mm) used for 
maraviroc quantitation method but the analytes were detected over 8.0 minute using AB 
SCIEX API 5500 mass spectrometer under positive electrospray mode. The optimized 
parameters and settings for mass spectrometry are listed in Table 5-1. The program of the 










m/z† of Ions  Operating Parameters 
 Precursor Product  DP‡ CE§ CXPll  
Method for maraviroc using API 4000 
Maraviroc  0.54  515.3 390.2  86 29 10 
2H6-maraviroc  0.54 520.6 389.1  80 29 10 
Method for M1 using API5500       
M1  3.1 530.2 405.2  161 29 12 
2H6-maraviroc  5.2 520.2 389.2  71 29 28 
†m/z, mass-to-charge ratio 
‡DP, Declustering Potential, V 
§CE, Collision Energy, eV 
















Table 5-2. Mobile phases program for detection of M1. 
 
Time (minutes) % Mobile Phase B 
0.0 4.0 
0.5 4.0 




















Pharmacokinetic analysis and statistical considerations 
Pharmacokinetic parameters of maraviroc and its metabolite M1, including area under the 
curve from time to infinity (AUC0-inf), area under the curve from time 0 to 32 h (AUC0-
32), plasma peak concentration (Cmax), time to reach Cmax (Tmax), half-life (T1/2), oral 
apparent clearance (CL/F) and volume of distribution (V/F) were estimated by 
WinNonlin (version 6.1, Pharsight, Cary, NC) using non-compartmental analysis. The 
values of time to Cmax were computed from the respective concentration–time curves. The 
metabolic ratio of maraviroc to metabolite M1 was calculated as the AUC ratio of 
maraviroc to M1 (AUCmaraviroc/AUCM1). Statistical analyses were performed with 
software R (version 2.15.1). Pharmacokinetic parameters and metabolic ratios among the 
three groups were compared using Kruskal-Wallis test; and differences between the 
groups with different CYP3A5 genotypes were assessed using a nonparametric statistical 
Mann–Whitney–Wilcoxon test. In addition, CYP3A5 genotype was treated as an ordered 
categorical variable (0, 1, and 2, for the homozygous mutant genotype, the heterozygous, 
and homozygous wild genotype, respectively) to evaluate the linear trend as one of the 
possible genetic models. We also valuated genotype as a dichotomous variable, 
combining heterozygous and homozygous mutant allele carriers for comparison with 
homozygous wild type allele CYP3A5*1 carriers to test a recessive pattern of inheritance 
and combining homozygous and heterozygous CYP3A5*1 allele carriers for comparison 
with homozygous mutant allele carriers to test a dominant genetic model. P < 0.05 was 
considered statistically significant. Linear regression graph was generated in SigmaPlot 
(version 12.3).  
 
CYP3A5 genotyping procedure 
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Genomic DNA was extracted from blood samples using QIAamp DNA Blood Mini Kit 
(Qiagen Inc, Valencia, CA). DNA fragments containing the polymorphic loci were 
amplified using iProofTM High Fidelity DNA polymerase obtained from Bio-Rad 
(Hercules, CA). Previously reported primers15,153,154 for polymerase chain reactions 
(PCR) and sequencing were used and the sequences are shown in Table 5-3. Optimum 
annealing temperature was determined using gradient PCR. The following program were 
used for PCR: (1) 98 °C for 30 s; (2) 98°C for 10s; (3) 65.2 °C  for CYP3A5*3, 59.0°C  
for *6, 57.8°C  for *7; (4) 72 °C for 45 s; repeat (2)-(4) for 35 cycles; and finally 72°C 
for 10 min. The PCR products were purified using QIAquick PCR purification kit 
(Qiagen, Inc) and sequenced at Synthesis and Sequencing Facility of The Johns Hopkins 
University School of Medicine using Sanger sequencing. The genotype of CYP3A5 was 
















                   














 Oligonucleotide Sequence 
PCR Primers  
CYP3A5*3 5'- CCTGCCTTCAATTTTTCACTG-3' 
 5'- GCAATGTAGGAAGGAGGGCT-3' 
CYP3A5*6 5'- GCTGCATGTATAGTGGAAGGAC-3'† 
 5'- GGAATTGTACCTTTTAAGTGGATG-3' 
CYP3A5*2/*7 5'- AAATACTTCACGAATACTATGATC-3' 
 5'- CAGGGACATAATTGATTATCTTTG-3' 
Sequencing Primers  
CYP3A5*3 5'- TAATATTCTTTTTGATAATG-3' 





A total of 34 subjects were evaluated for CYP3A5 genotype screening. Ten subjects were 
found to be homozygous for the wild type (29.4%, CYP3A5*1/*1), 10 were 
heterozygous (29.4%, 7 CYP3A5*1/*3, 2 CYP3A5*1/*6, 1 CYP3A5*1/*7,) and 14 were 
the mutant type (41.2%, 10 CYP3A5*3/*3, 2 CYP3A5*3/*6, 1 CYP3A5*6/*7, and 1 
CYP3A5*7/*7). No CYP3A5*2 was found. After genotypic screening, these potential 
study participants had a medical history, physical examination, and laboratory testing.  
Volunteers who were determined to be healthy were enrolled in the study with 8 people 
in each of the three CYP3A5 genotypic groups: (1) no CYP3A5*1 allele; (2) one 
CYP3A5*1 allele and one mutant allele; and (3) two CYP3A5*1 alleles. After receiving 
a single maraviroc dose, one volunteer in the homozygous wild type (CYP3A5*1/*1) was 
found to have no detectable maraviroc or maraviroc metabolites in any plasma samples. 
Consequently, this subject was excluded for data analysis and was replaced with another 
subject in the same genotype group. For the final 24 evaluable research participants the 
mutant group included 5 CYP3A5*3/*3, 2 CYP3A5*3/*6, and 1 CYP3A5*6/*7; the 
heterozygous group had 7 CYP3A5*1/*3 and 1 CYP3A5*1/*6; and the homozygous 
wild type group had 8 CYP3A5*1/*1. 
Demographics of subjects 
The age and weight of the 24 evaluable subjects ranged from 21 to 58 years (mean ± SD, 
41 ± 11years) and from 51.5 to 100.0 kg (mean ± SD, 78.2 ± 15.1 kg), respectively. Age, 
weight, body mass index (BMI), creatinine clearance (CrCL), total protein, albumin, 
bilirubin, and aspartate transaminase (AST) activity were similar among different 
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genotypic groups (Table 5-4). Alkaline phosphatase (ALP) and alanine transaminase 
(ALT) were lower in groups of people who carry two CYP3A5*1 alleles compared to the 
other two groups but the differences were not statistically significant. There were 6 
females with 2, 1, and 3 of them distributing in groups of people who carrying 0, 1 and 2 
CYP3A5*1 alleles, respectively. Among the 24 volunteers, 17 of them were black, 6 
were white, and one was Asian.  
Effect of CYP3A5 polymorphism on the pharmacokinetics of maraviroc and M1 
The mutant group had similar concentration-time profiles as the heterozygous group 
(Figure 5-2). In contrast, the homozygous wild type group exhibited lower mean plasma 
maraviroc concentrations at almost all blood collection times. The medians (interquartile 
range, IQR) of pharmacokinetic parameters of maraviroc and metabolite M1 are shown in 
Table 5-5. The biggest % of extrapolated AUC from the time of the last measurable 
concentration to infinity is 17.1%. The values of AUC0-32 are very close to values of 
AUC0-inf. Compared with the mutant group of people who do not carry any CYP3A5*1 
alleles, maraviroc median AUC0-inf was 41% lower and CL/F was 66% higher in the 
homozygous wild type group of people who carry two CYP3A5*1 alleles (p = 0.02 for 
both, Figure 5-2); V/F was 78% higher (p = 0.005); and Cmax was 33% lower but the 
difference was not statistically significant (p = 0.33). Compared to the other two groups, 
the heterozygous group who carry one CYP3A5*1 allele and one variant allele exhibited 
larger inter-individual variability. Median values of maraviroc Cmax, AUC0-inf, CL/F, and 
V/F in the heterozygous group were not statistically significant from those in either of the 




For metabolite M1, the plasma concentrations are lower in the mutant group compared 
with the other two groups (Figure 5-3). The M1 AUC0-inf in the homozygous wild type 
group is 157% relative to that in the mutant group with median (IQR) at 64.5 (57.4-82.9) 
h•ng/mL and 41.1 (32.2-53.1) h•ng/mL, p = 0.01), respectively. The M1 AUC0-inf of the 
heterozygous wild type group is 224% relative to that in the mutant group with median 
(IQR) of 91.9 (38.7-133.8) h•ng/mL but the difference was not statistically significant (p 
= 0.10). The M1 Cmax values were not statistically different among the three genotypic 
groups. Although not statistically significant, median Tmax in the homozygous wild type 
group was one hour earlier than that in the mutant group (p = 0.06).  
The influence of the CYP3A5 genotype was more evident in the AUC0-inf ratio of 
maraviroc to metabolite M1 (AUCmaraviroc/AUCM1), a parameter that is commonly used 
for comparing metabolizing enzyme activities. The three genotype groups were 
determined to be different populations for values of AUCmaraviroc/AUCM1 using Kruskal-
Wallis test (p < 0.001). Compared to the mutant group that has median (IQR) of 
AUCmaraviroc/AUCM1 at 49.5 (35.3-64.4), the homozygous wild type group and the 
heterozygous group were 64% and 52% lower with median (IQR) at 17.8 (15.7-22.5) and 
24.0 (19.8-25.7), respectively, and the differences are both statistically significant (p < 
0.001 for both, Figure 5-4). The homozygous wild type group and the heterozygous 
group were not statistically different from each other in AUCmaraviroc/AUCM1 (p = 0.13).  
Evaluation of genetic models with linear trend, recessive, and dominant assumption 
based on values of Bayesian Information Criterion (BIC) suggested that a dominant 
model for the CYP3A5*1 allele explained the data best.  
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The AUC0-inf ratio and plasma concentration ratio of maraviroc to metabolite M1 
(examining ratios at each sample time from 4 h to 10 h) showed strong correlations with 
R2 > 0.87 (r > 0.93). Starting at 6 h, some subjects had M1 plasma concentrations that are 
close to 0.25 ng/mL (within ± 20% for deviation), the lower limit of quantitation for M1 
concentration measurement assay. The AUC0-inf  ratios and plasma concentration ratios of 
maraviroc to metabolite M1 are highly correlated (R2 = 0.94, r = 0.97, p < 0.001, Figure 
5-5) at 4 h after the dose. Similar to AUC0-inf  ratios, plasma concentration ratios were 
statistically different among the three genotype groups using Kruskal-Wallis test (p < 
0.001). Compared to the mutant group that has median (IQR) of plasma concentration 
ratio of maraviroc to M1 at 41.6(36.4-64.9), the homozygous wild type group and the 
heterozygous group were 46% (p = 0.001) and 56% (p < 0.001) lower with median (IQR) 
at 22.6 (18.8-27.2) and 18.2(16.6-19.2), respectively, and the differences are both 
statistically significant (Figure 5-6). The homozygous wild type group and the 
heterozygous group were not statistically different from each other in plasma 
concentration ratio of maraviroc to M1 (p = 0.13). The effect of CYP3A5 genotype on 
the plasma concentration ratios of maraviroc to M1 had a similar pattern through all the 
times that samples were collected. It would be advantageous to use a single-point blood 
















Age# (year) 45.1 ± 12.7 39.4 ± 11.7 38.0 ± 8.8 
Weight# (Kg) 84.0 ± 15.6 76.7 ± 14.9 73.8 ± 14.5 
BMI†# (Kg/m2) 26.4 ± 4.5 24.9 ± 3.6 23.8 ± 3.6 
CrCL‡# (mL/min) 114.3 ± 28.8 103.2 ± 15.2 100.1 ± 30.2 
Total Protein# (g/dL) 7.0 ± 0.4 7.5 ± 0.4 7.1 ± 0.3 
Albumin# (g/dL) 4.6 ± 0.3 4.6 ± 0.1 4.5 ± 0.3 
Bilirubin# (mg/dL) 0.5 ± 0.2 0.4 ± 0.3 0.5 ± 0.2 
ALP# (IU/L) 73.3 ± 16.7 74.9 ± 17.0 54.9 ± 14.3 
ALT‡# (IU/L) 17.5 ± 4.5 18.5 ± 6.8 13.9 ± 3.4 
AST# (IU/L) 19.6 ± 2.9 22.4 ± 4.9 20.0 ± 2.9 
No. of Female/male 2/6 1/7 3/5 
Abbreviations: BMI, body mass index; CrCL, creatinine clearance; ALP, alkaline phosphatase; ALT, 
alanine transaminase; AST, aspartate transaminase.  
#Data are shown as mean ± SD.  
*Three groups of people based on CYP3A5 genotype: mutant (no CYP3A5*1 allele), heterozygous (one 
CYP3A5*1 allele and one mutant allele), and homozygous wild type (two CYP3A5*1 alleles). 
† Calculated as weight/(height × height). 
‡Calculated as [(140-age(year)) × weight (kg)]/[72 × serum creatinine concentration (mg/dL)] (multiply by 








Figure 5-1. The CYP3A5 homozygous wild type group has reduced plasma 
maraviroc concentrations. Mean (± SE) plasma concentrations of maraviroc after 
administration of a single dose of 300 mg maraviroc. Maraviroc concentrations are in 
linear-scale in (A) and log-scale in (B), respectively. N = 8 in each of the following 
groups: the mutant group who do not have CYP3A5*1 allele (blue line with diamonds), 
the heterozygous group who has one CYP3A5*1 allele and one nonfunctional allele (red 
line with squares), and the homozygous wild type group who have two CYP3A5*1 

















Table 5-5. Pharmacokinetic parameters (medians [interquartile range]) of 
maraviroc and metabolite M1. 





Maraviroc    
Cmax (ng/mL) 505(348-959.25) 435(209.75-889) 339.5(237-551.5) 
Tmax (h) 2.5(2.0-3.8) 2.0(1.2-3.0) 2.0(1.0-3.5) 
AUC0-32 (ng·h/mL) 2056(1454-2416) 1718(1200-2513) 1180(1038-1350) 
AUC0-inf (ng·h/mL) 2099(1422-2568) 1761(931-2640) 1238(1065-1407) 
% extrapolated AUC 2.4(2.1-2.8) 2.5(2.3-4.3) 3.6(2.6-4.4) 
T1/2 (h) 7.6(7.1-8.7) 7.4(6.5-10.8) 8.7(8.0-9.7) 
CL/F  (L/h) 146(117-212) 173(114-343) 243(213-282) 
V/F (L) 1757(1345-2235) 1697(1197-5234) 3126(2513-3711) 
M1    
Cmax (ng/mL) 10.1(6.5-18.5) 20.7(7.6-30.1) 15.9(15.2-18.9) 
Tmax (h) 3.0(2.3-3.8) 2.0(1.3-3.0) 2.0(1.0-2.0) 
AUC0-32 (ng·h/mL) 40.4(36.0-48.2) 90.1(49.2-117.9) 61.0(56.2-70.6) 
AUC0-inf (ng·h/mL) 41.1(32.2-53.1) 91.9(38.7-133.8) 64.5(57.4-82.9) 
% extrapolated AUC 2.4(1.3-5.9) 5.0(3.5-9.2) 4.2(2.6-6.6) 
AUC0-32 ratio 
(marviroc/M1) 49.2(35.6-63.1) 24.2(20.2-26. 3) 17.9(15.8-23.4) 
AUC0-inf ratio 
(marviroc/M1)1 
49.5(35.3-64.4) 24.0(19.8-25.7) 17.8(15.7-22.5) 
*Three groups of people based on CYP3A5 genotype: mutant (no CYP3A5*1 allele), heterozygous (one 





Figure 5-2. The CYP3A5 homozygous wild type group has increased maraviroc 
clearance and decreased exposure (AUC0-inf). (A) Maraviroc AUC0-inf.  (B) Maraviroc 



















Figure 5-3. The CYP3A5 mutant group has reduced plasma M1 concentrations. 
Mean (± SE) plasma concentrations of M1 after administration of a single dose of 300 
mg maraviroc. Metabolite M1 concentrations are in linear-scale in (A) and log-scale in 
(B), respectively. N = 8 in each of the following groups: the mutant group who do not 
have CYP3A5*1 allele (blue line with diamonds), the heterozygous group who has one 
CYP3A5*1 allele and one nonfunctional allele (red line with squares), and the 

















Figure 5-4. Carrying CYP3A5*1 allele caused reduction of area under the plasma 
concentration-time curve ratio of maraviroc to metabolite M1 
(AUCmaraviroc/AUCM1).  Statistical test was performed using Wilcoxon rank sum test in 

















Figure 5-5. Correlations between AUC0-inf ratios to plasma concentration ratios of 
maraviroc to metabolite M1 at 4 h after the maraviroc dose. Observed values (black 
dots) are presented with fitted linear regression line (the middle thick red line), 95% 
confidence interval (next outer curved lines) and the prediction band (broken line). Filled, 
circles, opened circles, and filled triangles represent data from people with 0, 1, and 2 
CYP3A5*1 allele, respectively. A data point (x = 310, y = 142) was determined to be an 
extreme value for data at both axes and thus excluded for the regression (R2=0.87 when 
included). The excluded data point was from an individual who was determined to have 
two non-functional alleles (*3/*3) and had the lowest M1 AUC0-inf and the highest AUC0-
inf  ratio of maraviroc to M1, indicating that this individual had the lowest CYP3A5 










R2 = 0.94 
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Figure 5-6. CYP3A5 genotype effect on plasma concentration ratios of maraviroc to 
M1 at 4 h. Individual data are shown with box-plot on the right for each group. Median 











The purpose of the investigation in this chapter was to extend our in vitro CYP3A5 
studies to this clinical study to further evaluate the impact of CYP3A5 genotype on the 
pharmacokinetics of maraviroc and a major oxidative metabolite M1. The results show 
that maraviroc AUC0-inf  in the CYP3A5*1 homozygous group decreased almost by half 
and oral apparent clearance increased significantly as compared to the subjects that do 
not carry the CYP3A5*1 allele; however, half-lives were similar between the two groups. 
The pharmacokinetic parameters of maraviroc in the mutant and heterozygous groups are 
similar to those reported values of previous studies in which CYP3A5 genotype was not 
characterized155,156. We observed large variability in maraviroc AUC0-inf in the 
heterozygous group, probably because when only one CYP3A5*1 is present, expression 
of CYP3A5 tends to be more easily influenced by other enzymes or transporters that play 
a role in absorption, disposition or elimination of maraviroc. CYP3A5 has been reported 
to be in linkage disequilibrium with CYP3A4 157,158,  the other important enzyme that is 
involved in maraviroc metabolism. Polymorphisms of CYP3A4 may also contribute to 
the pharmacokinetic variations of maraviroc. Epigenetic modifications are another 
potential reason for the variation of CYP3A4/5 expression although only a few studies 
have explored the mechanism in this field for CYP3A159-164. Besides CYP3A4 and 
CYP3A5, maraviroc is a substrate for P-glycoprotein (P-gp; also known as MDR1)165, a 
drug efflux pump located on intestinal epithelial cells which limits drug absorption, and 
organic anion transporting polypeptide 1B1 (OATP1B1), an influx transporter located on 
the basolateral membrane of hepatocytes mediating hepatic uptake of drugs. Their 
polymorphism-dependent expression has been reported to affect maraviroc plasma 
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concentrations165-169. The polymorphisms in these genes may contribute to the large 
variability. We will be examining the polymorphisms in these genes for our next step.  
The reduction of maraviroc exposure in the CYP3A5 wild type group supports our 
hypothesis that CYP3A5 genotype affects maraviroc pharmacokinetics. Our in vitro 
metabolism study suggested that CYP3A5 plays a major role in maraviroc oxidation170.  
Furthermore, in people who are CYP3A5 expressors, CYP3A5 represents at least half of 
CYP3A content in the jejunum and liver15, where metabolism occurs for orally 
administered drugs before entering systemic blood circulation. Therefore, the reduced 
maraviroc exposure we observed here in the CYP3A5 homozygous wild type group may 
be, or at least partially, due to reduced bioavailability caused by enhanced 
biotransformation from maraviroc to oxidative metabolites mediated by CYP3A5. The 
reduced maraviroc exposure is an impactful finding since more than 60% of African 
Americans are CYP3A5 expressors while current dosing recommendations were derived 
in a predominantly white population171. In combination with the fact that African 
Americans are disproportionately infected with HIV and at greater risk of acquiring HIV 
infection172, this finding may have implications for HIV treatment regimens and 
development of oral maraviroc for HIV prevention. When co-administered with strong 
CYP3A inducers like rifampin and efavirenz, maraviroc doses are recommended to be 
doubled to compensate the half-reduction in maraviroc AUC173,174. Because the CYP3A5 
genotype results in a similar magnitude of change, a doubling of the maraviroc dose in 
individuals with CYP3A5*1/*1 genotype would be warranted.  
In the previous chapter, we have demonstrated in vitro that using formation of one of the 
major monooxygenated metabolite M1 can be used to assess CYP3A5 activity. Since 
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maraviroc is an FDA-approved drug and has an excellent safety profile, maraviroc has 
great potential to assess CYP3A5 in vivo activity. Therefore, in this study, we also aimed 
to explore this utility of maraviroc in a clinical setting. In concordance with our 
hypothesis, we did find that people who carry CYP3A5*1 alleles had higher M1 AUC0-inf 
and Cmax compared to those who do not carry CYP3A5*1 alleles. The status of CYP3A5 
genotype status was well predicted by the AUC0-inf ratio of maraviroc to metabolite M1 
with more than 2 times bigger in people who do not carry CYP3A5*1 allele compared 
with those who carry CYP3A5*1 allele. Plasma concentration ratios of maraviroc to M1 
and the AUC0-inf ratios showed the strongest correlations at 4 h post maraviroc 
administration, indicating that single-point blood collections and plasma concentration 
measurement of maraviroc and M1 may be suitable to assess CYP3A5 activity to 
substitute intensive samplings for capture of the whole plasma concentration-time curve. 
This would add great value to the applicability of using maraviroc as a CYP3A5 
phenotyping tool. Furthermore, maraviroc does not modulate other CYP enzymes at the 
range of therapeutic concentrations124, it has the potential to be added to currently 
available phenotyping cocktails for other CYP enzymes.  
This investigation involved a small number of subjects in each of the three CYP3A5 
genotypic groups (N = 8). The results and optimal sampling times merit confirmation by 
studies with larger sample size. Future directions will include evaluation on changes of 
metabolic ratios of maraviroc to M1 in the presence of inducers and inhibitors that are 




In conclusion, despite the small size of the study groups, we observed a reduction of 
maraviroc AUC0-inf  nearly by half and 66% higher maraviroc oral clearance in group of 
people who carry two wild type CYP3A5*1 allele compared to those who do not have 
CYP3A5*1 allele. Maraviroc to metabolite AUC0-inf  ratios were more than 2 times higher 
in people who do not have CYP3A5*1 alleles relative to those who carry at least one 
CYP3A5*1 allele, indicating maraviroc has the potential to be used as a clinical 
phenotyping probe for CYP3A5. Moreover, measurement of plasma concentration ratio 
of maraviroc and metabolite M1 at 4 h following a single 300 mg oral dose of maraviroc 
could represent a useful surrogate measure for AUC0-inf ratio of maraviroc to M1 and an 
accurate indirect marker of the CYP3A5 phenotype in healthy volunteers. The clinical 
utility of using maraviroc as a CYP3A5 phenotyping probe drug, as supported by this 
study could be helpful for predicting drug-drug interactions and identifying individuals 











Chapter 6 – Conclusions 
This thesis demonstrates pharmacokinetic variations of drugs related to three of the 
world’s most devastating disease, HIV infection, tuberculosis, and malaria. We 
characterized drug-drug pharmacokinetic interactions mediated by the most important 
drug metabolizing enzymes CYP3A4/5 and identified the anti-HIV drug maraviroc as a 
phenotyping probe both in vitro and in vivo to assess the highly variable isoenzyme 
CYP3A5 caused by genetic polymorphisms.  
In Chapter 2, we performed a dose escalation study for anti-tuberculosis drug rifapentine 
to evaluate its pharmacokinetics with new daily dosing regimens in healthy volunteers 
and found rifapentine had a less than dose-proportional increase in both AUC and Cmax as 
dose increased. We used a chemical analogue that is also known as a CYP3A inducer, 
rifampin, as a comparator drug to study the effect on a CYP3A4/5 substrate drug, 
midazolam, and found that rifapentine strongly induced CYP3A4/5 enzyme in a dose-
independent manner at a degree that was stronger than the induction caused by rifampin. 
In chapter 3, we conducted a drug-drug interaction study to assess long-term use of a 
CYP3A4/5 inhibitor, ritonavir, containing anti-HIV drugs lopinavir/ritonavir (or LPV/r) 
on CYP3A substrate quinine, a drug used for treatment of malaria with a low therapeutic 
window. In the presence of steady-state LPV/r, we found significant decrease in the 
exposure (Cmax and AUC) of quinine and its major active metabolite 3-hydroxyquinine 
(both total and protein bound free) as well as the metabolite to parent drug AUC ratio 
compared with those when quinine was administered alone.  
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The CYP3A substrate drugs as described above, midazolam and quinine, are metabolized 
by both CYP3A4 and CYP3A5. Therefore, the individual contributions of CYP3A4 and 
CYP3A5 cannot be differentiated due to the high similarity between the two enzymes. 
Since CYP3A5 expression exhibits high variability due to genetic polymorphisms, 
discovery of a CYP3A5 selective substrate will be helpful in assessment of CYP3A5 
contribution in drug-drug interaction studies and identification of CYP3A5 substrates, 
inducers and inhibitors.  
In chapter 4, through a comprehensive analysis of metabolism for the anti-HIV drug 
maraviroc, we determined that CYP3A5 was the principal enzyme responsible for the 
formation of an abundant metabolite of maraviroc, named M1, resulting from 
oxygenation of the dichlorocyclohexane ring. CYP3A5 has 23 times higher enzyme 
capacity for M1 formation compared with CYP3A4. We then confirmed the role of 
CYP3A5 in M1 formation by using human liver microsomes isolated from CYP3A5-
genotyped donors. By exchanging divergent residues between CYP3A4 and CYP3A5 
using site-directed mutagenesis followed by metabolic activity measurement of the 
mutated enzymes, we discovered an amino acid residue 57 that may play a role in the 
differential activities of these enzymes towards maraviroc biotransformation. From this 
study, we identified the anti-HIV drug maraviroc as a candidate for development as a 
CYP3A5 phenotyping probe and provided novel mechanistic insight into the role of 
divergent amino acids of CYP3A4 and CYP3A5 in influencing their catalytic activities. 
The favorable safety profile of maraviroc renders this drug an attractive candidate for 




In Chapter 5, we conducted a clinical study in CYP3A5-genotyped healthy volunteers to 
further investigate the clinical value of maraviroc in assessing CYP3A5 activity by 
evaluating the influence of CYP3A5 genotype on pharmacokinetics of maraviroc and the 
metabolite M1 primarily formed by CYP3A5. Following a single oral dose of maraviroc, 
subjects in the homozygous wild type group had 41% lower maraviroc AUC, 66% higher 
maraviroc oral clearance, and 57% higher M1 AUC compared with the mutant group. 
The AUC ratio of maraviroc to M1 in mutant group doubled when compared to 
heterozygous and homozygous wild type groups, confirming the value of maraviroc as a 
substrate drug to assess CYP3A5 activity in a clinical setting. In addition, plasma 
concentration ratio of maraviroc to M1 correlated highly with the AUC ratio at 4 h after 
dose administration, suggesting that sing-point blood collection may be used for CYP3A5 
activity measurement.  
In summary, this thesis has identified pharmacokinetic variations of anti-infective agents, 
their effect on pharmacokinetics of CYP3A substrate drugs, and discovered the anti-HIV 
drug maraviroc as a phenotyping probe to assess the highly variable enzyme CYP3A5 
both in vitro and in vivo. The results from this thesis will be helpful to inform dosing 
regimen selection to achieve treatment success while minimizing drug-related toxicity. 
Our discovery of maraviroc as a CYP3A5 probe will have a broad application from bench 
to bedside to identify CYP3A5 substrates, inducers, and inhibitors, which will help to 
increase efficiency of drug discovery/development and reduce the risk of developing side 
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